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Introduction 
Several major guidelines and organizations now advocate routine assessment of 
cardiovascular risk using Framiugham-derived coronary heart disease (CHD) risk 
scores.
1
-
3 Yet there is relatively little data on whether the routine use of such 
assessments translates into improved clinical outcomes. In particular, little is 
known about how knowledge of a patient's calculated 10-year CHD risk affects a 
physician's perception of the patient's risk and whether that in turn translates into 
improved adherence to published guidelines for the primary prevention of CHD. 
This paper is organized into three major sections: First, a thorough review of the 
theoretical benefits of global CHD risk calculation is presented. Following this is 
a systematic review of the literature. supporting the efficacy of incorporating 
Framingham-derived global risk scores into routine clinical practice. Lastly we 
present the methods and preliminary results of a study designed to determine 
whether physicians make better CHD prevention decisions when they interpret a 
patient's risk factor information in the context of a calculated 10-year risk of 
CHD than when they use the risk factor information alone. 
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Background: 
Cardiovascular Disease Prevention and the 
Rationale for Global CHD Risk Calculation 
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The Burden of Suffering Associated with Cardiovascular Disease 
in the U.S. 
Almost one million Americans die of cardiovascular disease (CVD) each year, 
which is more than cancer, chronic obstructive lung disease, accidents, diabetes, 
and influenza/pneumonia combined. The major forms of CVD, heart disease and 
stroke, account for one of every five and one of every 15 deaths respectively, and 
together they account for more than one of every three deaths in the U.S each 
year. This is true regardless of gender or ethnic group. Despite a 26% decline in 
the death rate from CVD over the last decade, the actual number of CVD deaths 
has declined by only approximately 9.4% because of the increasing prevalence of 
CVD and its risk factors in our society. 4• 5 
Sixty-four million Americans currently have some form of CVD, and each year 
they are joined by 1.9 million more (700,000 new myocardial infarctions [MI], 
500,000 recurrent Mis, 500,000 new strokes, and 200,000 recurrent strokes)4• 
These numbers are expected to increase over the next decade given the growing 
number of older Americans and the high prevalence of CVD risk factors. 
Although the incidence and prevalence of CVD clearly increase with age, this is 
not simply a problem of the elderly. In fact, approximately 16.8% of all heart 
disease deaths occur in people under 65 years old. 4• 6 
Along with the staggering human toll of CVD, the economic impact is significant. 
CVD is the #1 disease category listed on hospital discharges (6.2 million/year), 
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and it accounts for 71 million physician office visits, 5.6 million outpatient 
department visits, and 4.2 million emergency department visits each year.4• 7• 8 In 
2004, the direct and indirect costs due to CVD are estimated at $368.4 billion.4 
Opportunities for Prevention 
Cardiovascular disease and its risk factors are among the most common 
conditions encountered by primary care clinicians,7 and an increasing number of 
people now have multiple risk factors4• 9• 10 Table 1 summarizes the prevalence of 
the various CVD risk factors and puts these numbers into the perspective of the 
average clinician's patient panel. The numbers vary depending on the location 
and nature of practices, but the overall message is clear: every clinician sees many 
patients who either already have CVD or are at risk for developing it. 
Table 1: Prevalence of CVD and Its Risk Factors U.S. Adults" 
Prevalence 
in U.S. 
(%) 
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#of Patients in an average 
Primary Care Practice Panel 
With Condition (Based on 
1490 
Prevalence estimates derived from NHANES III/IV and CDC/NCHS 
data as listed in American Heart Association Heart Disease and Stroke 
Statistics - 2004 Update. Dallas, TX: American Heart Association; 
2003. Prevalence of multiple risk factors is derived from Paynter et al. 
Declining prevalence of no known major risk factors for heart disease 
and stroke among adults -- United States, 1991-2001. MMWR. 
2004;53(1):4-7. 
•White and African-American men and women over age 20, except for 
tobacco use and physical inactivity statistics, which refer to adults 2:18 
years. 
nCardiovascular disease is defmed as !CD/I 0 codes !00-99 and Q20-
28. Coronary Heart Disease is defmed as ICD/10 codes !20-25. Stroke 
is defined as ICD/10 codes !60-69. 
*One or more of: hypertension, elevated cholesterol, diabetes, tobacco 
use, obesity. 
** JNC 711 
***As of2000, there were 67.1 Internists and Family Practioners per 
100,000 U.S. population, this translates to 1490 patients per primary 
care physician12 The number of patients was calculated by multiplying 
the prevalence of the risk factor by 1490. 
APhysical inactivity is defined as not meeting one of the following 
standards: activity of moderate intensity for 2:30 minutes per day on 2:5 
days per week or vigorous intensity for 2:20 minutes per day on 2:3 days 
per week. 13 
Although sobering, these estimates point out the substantial opportunity that 
exists for preventive interventions to make a difference in the lives of a large 
number of patients. Much of this work has to be done at a population level, but 
through consistent application of evidenced-based preventive interventions, 
clinicians are in a position to help reduce the number of individuals in their 
communities who will have a new or recurrent CVD event over both the short-
and long-term. Achieving this, however, requires not only a familiarity with 
guidelines, but also an understanding of overarching framework of CVD 
prevention. 
7 of102 
The Continuum of Cardiovascular Disease and Prevention 
Prevention can be conceptualized as a continuum with components that 
correspond to the underlying burden of atherosclerotic disease, and thus to the 
risk of CVD events in the target patient population (Figure 1 ). 
[Figure 1 is located at the end ofthe paper] 
Primordial prevention targets populations without any underlying f 
atherosclerosis and can be thought of as the prevention of CVD by preventing the 
development of CVD risk factors in the first place14-17 Interventions in this 
category include counseling for healthy diet, physical activity, obesity, and 
smoking prevention. Although individual counseling of patients is desirable, 
these interventions are most effective when part of a more intensive, 
multidisciplinary program with a strong community-based component. The goal 
of these activities is to decrease the prevalence of risk factors across all of society, 
which in turn translates into a reduction in the number of people developing CVD. 
Primary prevention refers to efforts to modify existing risk factors with the aim 
of delaying or preventing new-onset CVD. 18 These efforts target a heterogeneous L 
group of asymptomatic people without clinical cardiovascular disease who are at 
varying levels of risk depending on the number, combination, and magnitude of 
their risk factors. While some patients are at low risk, others have risk that equals 
that of patients who already have CVD. 
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Over time, and with the accumulation of risk factors, patients will develop 
varying degrees of subclinical atherosclerosis. These patients are at considerable 
risk for experiencing a CVD event (MI, stroke, TIA, etc ... ) in the short term. In 
these patients, the goal is to retard the progression of subclinical disease and 
prevent a first CVD event. Prevention of a first CVD event in patients who have 
vascular disease but who hav not yet suffered a clinical event is termed 
secondary prevention. 
F 
Unlike primordial, primary, and secondary prevention, all of which aim to prevent 
a first CVD event, the goal of tertiary prevention is to prevent recurrent events 
in people who have already had a clinical CVD event. These people are at very 
high risk for another event, and they require aggressive risk reduction strategies. 
The framework provides insight into the manner in which the different CVD 
prevention guidelines fit together. It also emphasizes that each level of 
prevention is a stepping stone into the next, such that the preventive activities that 
are begun in each stage are added on to the ones begun previously. The manner 
in which the different CVD prevention guidelines fit into this framework is shown 
in Appendix 1. 
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The Prevention Gap 
Despite the availability of numerous guidelines and abundant evidence regarding 
the efficacy of interventions to prevent CVD, the majority of people with CVD 
risk factors do not have them under adequate control. 19-23 The facts are startling: 
69% of hypertensive patients do not have their blood pressure under control, and 
almost half are not even on any treatrnent.22 Additionally, only 18% of patients 
with dyslipidemia have their cholesterol treated to goallevels_19 The reasons for 
this are complex and involve the interplay of multiple patient-, physician-, and 
health care system-related factors. 
For physicians, implementing evidenced-based guidelines into practice is 
challenging. In part, this is due to the sheer number of existing guidelines and the 
time constraints of everyday practice.24 Other factors include competing patient 
demands, issues with patient adherence, misunderstanding about the proper focus 
of preventive efforts (on the part of both the patient and physician), lack of 
consistency among different guidelines, and confusion caused by rapidly 
advancing science. The latter is especially true in the area of CVD prevention 
where new biomarkers and diagnostic tests are announced frequently. 
An additional factor that may play a role in the poor implementation of 
interventions aimed at preventing CVD is that physicians have difficulty 
accurately estimating risk. Risk assessment is important because it not only helps 
identify candidates for preventive interventions, but also because it guides the 
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intensity and types of interventions that are chosen?5 Unfortunately, estimating 
risk is not as straightforward as it may seem, and several studies have shown that 
physicians vary significantly in their ability to accurately estimate a patient's risk 
ofCVD.26'34 It follows that inaccurate risk estimation may contribute to difficulty 
in appropriately implementing CVD-preventing interventions. 
Integrating Risk Information: The Rationale for Global 
Cardiovascular Disease Risk Scores 
Risk Stratification 
Over the last decade several authorities have proposed that risk stratification (i.e. 
estimation of a patient's overall risk of CVD) should be the first step in deciding 
how to proceed with preventive interventions. 
The rationale for this recommendation arises from the fact that the balance of 
benefits and harms for treating CHD risk factors varies across the spectrum of 
CHD risk. This is because several "traditional" risk factors demonstrate a fairly 
linear relationship with the incidence of CVD. 35• 36 such that the risk of CVD is 
reduced/increased by a relatively constant proportion across the spectrum of CHD 
risk. As a corollary, the absolute benefit caused by a change in risk factor level 
depends on the patient's baseline level of risk. 
This linear association and its implications are the underpinning of what most 
physicians understand intuitively; that is, as the risk of CVD increases, the net 
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benefits of treatment increase as well. The corollary to this is that as baseline 
risk increases, the benefits of treatment will outweigh potential harms by a greater 
margin since the harms of a particular treatment are generally independent of 
CVD risk and therefore tend to remain at a relatively fixed level (Figure 2i7• 
With this in mind, it becomes clear that estimation of baseline risk is central to 
balancing the benefits and harms of any intervention. 38 
Fig!. I'~ 2: Th;;, r41eti"Mhif:! bi!'1Wl!'en C'JD 11~ t~rtd lh;;o 
Benefits md Harms rl T!'fatment 
Benefit increases as CVD risk increases, but hann is 
constant because it is generally independent of CVD 
risk. WhenCVD risk exceeds a certain threshold, the 
benefits of treatment outweigh the hanns. (Adapted 
from: Glasziou P, Irwig M. An evidence based 
approach to individualising treatment. BMJ. 
1995;311; 1356-1359.) 
Hlql 
The clinical utility of these observations can be illustrated using the example of 
aspirin. Table 2 shows that when aspirin is used for primary prevention, a greater 
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number of events are prevented as the baseline risk for coronary heart disease 
increases. In contrast, the risk of gastrointestinal bleeding from aspirin remains 
constant across all CHD risk levels.3 The number of coronary heart disease 
events prevented begins to exceed the number of adverse events at a 5-year risk of 
3%. Below this threshold level aspirin therapy has the potential to cause more 
harm than benefit, and thus should be avoided. 
[Table 2 is located at the end of the paper] 
Framingham Risk Scores 
It is possible to arrive at a reasonably good estimate of CVD risk by screening for 
the traditional CVD risk factors and then calculating a patient's global 10-year 
coronary heart disease (CHD) risk score. This score, which can be easily 
calculated using a number of readily available tools,39 is based on data collected 
from the Framingham Heart Study and the Framingham Offspring Study. In 1998 
a simplified and updated algorithm was published that integrated the categorical 
approaches that are a part of blood pressure and cholesterol guidelines.36 
The risk estimate is derived from a prediction model that was developed using 
data from 5345 subjects (47% male) who were free of clinically apparent 
coronary heart disease (CHD) and were between the ages of 30 and 74 years old 
at the time of enrollment in the study. The patients were followed for 12 years in 
order to collect end-point information. Multivariable and logistic regression were 
used to develop models for the 1 0-year incidence of CHD events, and the J3-
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coefficients from the model were used to develop a point system for summing the 
effects of various risk factors. Table 3 lists the risk factors included in the 
original model. It is notable that obesity, triglycerides, physical activity, and 
family history, which are all established risk factors, are not included in the 
model. It is not clear whether the inclusion of these in the model would provide 
significant additional information because these risk factors are at least partially 
collinear with the risk factors already included in the model, and therefore the 
independent contribution of these risk factors would is obscured.25 
Table 3: Risk Factors Included in Framingham Risk Score 
Risk Factors Definition Used in Study 
Smoking Regular smoking during the past 12 mouths 
Diabetes Patient on therapy for diabetes , or fasting blood glucose> 140 mg/dl 
Blood Pressure Categorized by JNC-V definitions 
Total or LDL- mg/dl 
Cholesterol 
HDL-cholesterol mg/dl 
Age years 
The Framingham model can be used to predict a patient's 10-year risk of "Total 
CHD" (angina, recognized and umecognized MI, unstable angina, and CHD 
death) or "Hard CHD" (MI and CHD death only). Appendix 2 presents a simple 
point-based method for calculating a Framingham risk score. Although absolute 
risk estimates are used most often, relative risk can also be calculated. The 
reference group is a "low risk" cohort, defined as non-diabetic non-smokers with 
BP<l20/80 mmHg, total cholesterol <200 mg/dl (LDL-C < 130 mg/dl), and HDL-
14ofl02 
C 2: 45 mg/dl (men) or 2: 55 mg/dl (women). This definition of "low risk" is 
based on data from the Multiple Risk Factor Intervention Trial (MRFIT).40• 41 
The model adds a degree of perspective because it reveals that different risk 
factors impart a relatively comparable degree of risk -- generally on the order of a 
RR 1.2-2.0 (Table 4). The similar influences of the different risk factors is not 
widely appreciated.18• 36 Additionally, the model highlights the importance of age 
as a risk factor: even in the absence of other risk factors, absolute risk for CHD 
rises progressively with age (Table 5). The higher baseline risk associated with 
older age points out the substantial opportunity for prevention in the elderly. 18 
[Tables 4 and 5 are located at the end ofthe paper] 
Clinical Relevance of Risk Scores 
Risk scores help clinicians classify patients as being either at low-, intermediate-, 
or high-risk of coronary heart disease events over the next 10 years (short-term 
risk). Definitions for the cut-offs between levels of risk, along with the general 
implications of each level, can be found in Table 6. 
[Tables 6 is located at the end of the paper] 
Although generally accepted, the cut-offs between risk levels have some 
uncertainty about them, 25• 42 and the they must be viewed as guides rather than as 
absolute indications for any particular therapy. This uncertainty exists because 
definitions of risk must take into account more than just the balance of the 
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potential harms and benefits of a particular treatment. Issues of cost-effectiveness 
and individual patient preferences also must play a role. The distinctions become 
particularly hazy among patients that fall into the intermediate risk category. 
Although most U.S. authorities agree that those with a 10-year CHD risk of>20% 
can be considered to be at high short-term risk and therefore candidates for more 
aggressive risk reduction,2• 25 there is less agreement on the boundary between 
low- and intermediate risk, with some arguing that 5% to 6% is a more 
appropriate cut-off for the "low risk" designation because it limits the category to 
patients who are less likely to have any of the traditional CHD risk factors other 
than age.43 
The issue is further complicated because low short-term risk does not necessarily 
imply a low long-term risk. For example, a 50 year old man with a I 0-year risk 
of 8% has an approximately 24% risk of having a CHD event over the next 30 
years. Depending on the patient's general state of health this may be tum out to 
be significant. 
Limitations 
There are several important limitations to Framingham-derived global risk 
scores:25 
They are meant only for primary prevention and are invalid for patients 
who already have CHD -- these patients are already at high risk and 
require aggressive risk reduction. 
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Scores do not apply to severe forms of any particular risk factor, and they 
probably underestimate risk in those situations. 
Measurements were made several years ago and it is possible that the 
absolute level of risk associated with a particular risk factor in the 
population has changed over time. 
The study population was relatively homogeneous, and estimates may not 
apply to different populations 
The magnitude of risk reduction achieved by modifYing each risk factor 
may not equal (in reverse) the increment of risk conferred by that risk 
factor. 
Scores are average values and they may vary among individuals 
depending on other risk factors not included in equation that might modify 
overall risk. 
Validity 
Despite these limitations, global CHD risk scores have been demonstrated to be 
valid among both white and black Americans, and they perform acceptably in 
Hispanic Americans.25• 44 People of South Asian origin appear to have about 
twice the absolute risk of whites when living in America, while East Asian 
Americans may have a lower absolute risk than other ethnic groups in the U.S. 
However, while absolute risks may be different, the relative risk conferred by risk 
factors is probably similar for all ethnic groups.25 
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Other Factors -
CHD Equivalents 
Although diabetes is included in the scoring system, its presence has now been 
elevated to a CHD equivalent, and therefore diabetic patients reqmre more 
aggressive risk reduction than is indicated by their risk score? Although the 
elevation of diabetes to a CHD equivalent is a useful clinical decision tool 
because it reminds physicians that over the long-term, diabetics are at higher risk 
of developing cardiovascular disease, it can also be somewhat inaccurate because 
not all diabetics have a short-term CHD risk of >20%. This is particularly true of 
younger patients. 
The distinction is not evident, however, when using newer risk scoring tools (such 
as those available through the National Cholesterol Education Program) because 
these tools preclude calculation of a numerical risk once "diabetes" has been 
noted. In these instances, the answer "CHD equivalent" is returned instead of a 
numerical estimate of risk. Given that diabetics generally are at higher risk, the 
distinction is somewhat academic for most patients, but it is worth noting. 
On the other hand, peripheral vascular disease and cerebrovascular disease are 
true CHD equivalents. Considering them as such underscores the fact that 
atherosclerosis is a systemic disease that can affect the entire vasculature. 
Patients with these disorders are automatically included in the high risk category. 
The Metabolic Syndrome 
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Approximately 44% of American adults over 50 years old have the metabolic 
syndrome (defined by the National Cholesterol Education Program [NCEP] as 
three or more of the following: (!) abdominal obesity (waist circumference >40 
inches for males, >35 inches for females), (2) systolic blood pressure 2': 130 
mmHg or diastolic blood pressure 2': 85 or on anti-hypertensive medication, (3) 
fasting triglycerides of2': !50 mg/dl, (4) HDL-C <40 mg/dl [males] or< 50 mg/dl 
[females], (5) impaired fasting glucose [110-125 mg/dl]). The metabolic 
syndrome is associated with an increased risk of CHD (OR 2.07, 95% CI !.66-
2.59), and the importance of its detection is highlighted in the most recent NCEP 
guidelines.2' 45 Although some components of the metabolic syndrome are 
included among the major risk factors used in Framingham calculations, not all 
elements are accounted for, and the true risk for patients with the metabolic 
syndrome may be underestimated by Framingham global risk scores?· 18• 4547 
This concern has been called into question, however, by an analysis of data from 
NHANES III, which suggests that Framingham scores may indeed be accurate in 
patients with metabolic syndrome. In this study, the metabolic syndrome was a 
significant predictor of CHD in univariate analysis. However, in a multivariable 
model that included waist circumference, triglycerides, HDL-C, blood pressure, 
impaired fasting glucose, diabetes, and metabolic syndrome, only HDL-C, blood 
pressure, and diabetes were significant.45 This result suggests that the metabolic 
syndrome is highly correlated with the traditional risk factors, and thus 
Framingham scores may indeed be valid in this population. 
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Novel Risk Factors and New Screening Tests 
Over the last decade a variety of new risk factors and screening tests for CVD 
have been proposed (Table 7), and some, such as C-reactive protein (CRP), have 
received wide attention in both the medical and lay press. Many of these tests 
show significant promise for the early detection of CVD, and it has been proposed 
that they may be useful in identifying low- and intermediate-risk patients who 
need more aggressive risk reduction.48"53 However, it is not clear whether any of 
these tests provide clinically useful information that cannot be derived from 
screening for the traditional risk factors - especially in patients deemed to be at 
either low- or high- risk for CVD.54·60 
[Table 7is located at the end ofthe paper] 
This uncertainty exists even with the most highly touted novel marker, CRP; 
despite over 22 published studies, there is still much debate about the extent to 
which it can add to the prediction of CVD risk over and above the traditional risk 
factors. Most notably, a recently published large cohort study and updated meta-
analysis concluded that although CRP is indeed a statistically significant predictor 
of CHD, the strength of the association is markedly attenuated when adjustments 
are made for traditional risk factors.61 This study followed a recent systematic 
review that also examined the evidence for CRP and concluded that the optimal 
use for CRP in routine screening and risk stratification remains to be 
determined. 55 
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Similar situations exist with all of the other novel risk factors and new screening 
tests that have been proposed. Specifically, no controlled trials of screening for 
and treating any of the novel risk factors (or using the new screening tests) have 
been conducted to determine whether integration of such tests in clinical practice 
makes a difference in patient outcomes. Therefore, although it is likely that some 
of these risk factors and screening tests will eventually play a key role in 
prevention, the most appropriate way to use them is still unclear. Cost 
b 
effectiveness also remains to be determined. Until these issues are resolved, the 
greatest clinical benefit can probably be derived by continued focus on screening L 
for and treating traditional CVD risk factors, which, as noted above, still remain 
woefully under-treated in the U.S. 
Is There Evidence Supporting the Use of Global Risk Scores? 
As noted above, the use of global risk scores has several potential benefits: 
Improved physician estimation of a patient's CVD risk 
Improved identification of high-risk patients who require immediate 
attention25 
Improved balancing of potential benefits and harms of preventive 
interventions 
Ability to modify the intensity of preventive interventions depending on 
h b 1. . f . k25 62 t e ase me estimate o ns · 
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Motivation for both physicians and patients to overcome the clinical 
inertia that often prevents an effective intervention from being initiated63' 
64 
Improved patient understanding of the rationale for treatment 
Improved patient understanding of the individual's risk ofCVD33 
Improved patient adherence to prescribed risk-reducing interventions65 
Improved cost-effectiveness of risk-reducing interventions66 
These proposed benefits address a number of factors that are perceived as being 
responsible for the current under-utilization of interventions that reduce the risk of 
CVD, Underlying all of them is the assumption that the routine use of 
Framingham global CHD risk scores will lead to improved clinical outcomes, 
In many ways this makes sense, It is clear that some form of risk estimation is a 
requisite part of good preventive medicine, and it is also clear that both physicians 
and patients have difficulty accurately estimating risk, It follows from these 
observations that a tool that corrects misperceptions and raises awareness of risk 
should be usefuL To some extent this appears to be the logic behind the various 
recommendations for the use routine use of global risk scores, 
Although this may in fact be the case, there is relatively little data on whether the 
routine use of Framingham-derived global risk calculations actually translates into 
improved clinical outcomes, In an era of evidence-based medicine this is a 
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seeming paradox: widespread support of a screening test without any evidence of 
benefit. Even more interesting is the fact that this is done with the goal of 
increasing the use of other evidence-based interventions. This situation likely 
stems from four factors. First, as described above, the risk scores themselves are 
valid predictors of CHD risk. Second, their use is associated with a very low cost 
in terms of both time and money. Third, there is an assumption that no possible 
harm can arise from using them, and lastly, and perhaps most importantly, there is 
such an enormous underutilization of appropriate CVD risk-reducing 
interventions that any tool that is perceived to be a useful remedy to the situation 
is welcomed. 
The goal of this paper is not to refute this line of reasoning. Rather, we hope to 
shed light on the issue of whether there is evidence that the routine use of global 
risk scores is in fact associated with clinical benefits. Two approaches are used. 
First, the result of a systematic review of the literature in this area is presented. L 
Since it was expected that there would be a paucity of studies addressing this 
issue, the systematic review was performed concurrent with a small study that 
attempts to test the hypothesis that physicians make better CHD prevention 
decisions when they interpret risk factor information in the context of a global 
risk score than when they view the risk factor information only. The methods and 
;----
preliminary results of this study are presented following the systematic review. 
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Is the Routine Use of Global Coronary Heart 
Disease Risk Scores Associated with Clinical 
Benefits? 
A Systematic Review of the Literature 
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Methods 
Questions to be reviewed: 
The primary question addressed by this review is: Does routine calculation of a 
global CHD risk score by physicians (as opposed to either simple risk factor 
counting or no formal assessment of risk) lead to clinical benefits? For the 
purposes of this review, clinical benefits are broadly defined as either (1) 
improved physician adherence with evidence-based guidelines for the primary 
prevention of CVD, (2) increased appropriate prescribing of risk reducing 
therapies, (3) improved control of patient CVD risk fuctors (i.e. blood pressure, 
cholesterol), (4) a reduction in CVD events, or (5) increased patient adherence 
with therapies targeted at the primary prevention of CVD. 
Given that any screening test may be associated with harm, a secondary question 
is whether there are any harms associated with screening using global risk scores. 
Search Strategy 
We searched MEDLINE (1966- April 2004) and the Cochrane database using 
MeSH terms and four distinct search strategies. This broad search strategy was 
used in order to increase the likelihood of finding all pertinent studies. The search 
was limited to studies in hnmans and to the English language literature. 
Search strategy I: "Cardiovascular Diseases/pc [Prevention & 
Control]" AND "Risk Assessment" 
Search strategy 2: ("Heart Diseases" OR "Vascular Diseases") AND 
"Risk Assessment" AND ("Feasibility Studies" OR Cross-Sectional 
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Studies" OR "Follow-up Studies" OR "Longitudinal Studies" OR 
"Prospective Studies" OR "Cross-Over Studies" OR "Intervention 
Studies" OR "Cohort Studies" OR "Epidemiologic Studies" OR 
"Case-Control Studies" OR "Retrospective Studies" OR "Multicenter 
Studies" OR "Evaluation Studies") 
Search strategy 3: "Cardiovascular Diseases/pc [Prevention & 
Control]" AND ("Framingham.mp" OR "Global Risk.mp" OR 
"Global Risk Score.mp" OR "Coronary Risk.mp" OR "Coronary Risk 
Score.mp" OR Cardiovascular Risk.mp" OR "Cardiovascular Risk 
Score.mp'') AND ("Feasibility Studies" OR Cross-Sectional Studies" 
OR "Follow-up Studies" OR "Longitudinal Studies" OR "Prospective 
I 
t Studies" OR "Cross-Over Studies" OR "Intervention Studies" OR 
"Cohort Studies" OR "Epidemiologic Studies" OR "Case-Control 
Studies" OR "Retrospective Studies" OR "Multicenter Studies" OR 
"Evaluation Studies") 
Search strategy 4: "Cardiovascular risk score$.mp" OR "Coronary risk 
score$.mp" 
Study Inclusion Criteria: 
We included studies of any design as long as they met the following criteria: (1) 
study population consisted of asymptomatic adults 2: 18 years old with no prior 
history of CVD; (2) Global CHD risk calculation was specified as the primary 
study intervention (multi-factorial interventions were acceptable as long as the 
calculation of global CHD risk was the most prominent part of the intervention); 
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(3) There was clear documentation of the calculation of a global CHD risk score 
by a physician or other health care provider as part of an individual patient 
encounter (Questionnaire-based studies were considered acceptable as long as 
they were designed to simulate clinical encounters with patients); and (4) One or 
more of the following endpoints was used: (i) rates of prescribing for aspirin, anti-
hypertensive medication, or lipid-lowering medication; (ii) change in patient 
blood pressure or cholesterol levels; (iii) physician compliance with guidelines for 
CVD prevention; (iv) rate of CVD events (defined here as new onset 
stroke/transient ischemic attack, myocardial infarction, acute coronary syndrome, 
stable angina, peripheral vascular disease, carotid artery disease, or cardiac 
death); (v) patient adherence with therapy; or (vi) harms of CHD risk calculation. 
We considered Framingham-derived estimates preferable, however other scoring 
systems were acceptable as long as they presented risk in a comparable fashion 
(i.e. as an absolute risk estimate or in terms of risk categories -low, intermediate, 
high). Additionally, in order to be included, studies had to provide enough 
information so that it was possible to determine the method of global risk 
calculation as well as the manner in which the risk assessment was used in the 
clinical encounter. 
Study Exclusion Criteria: 
We excluded studies for the following reasons: (1) they involved children or 
adolescents; (2) risk calculation was performed primarily by patients; (3) risk 
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calculation was performed outside of a clinical setting; or ( 4) the study primarily 
addressed secondary prevention of CVD. 
Data Extraction Strategy 
A single reviewer determined which studies were eligible for inclusion in the 
review and then independently abstracted the data from the studies into tables for 
analysis. A second reviewer checked these tables for accuracy and disagreements 
were resolved by discussion between the reviewers. 
Assessment of Study Quality 
We assessed study quality using criteria proposed by the U.S. Preventive Services 
Task Force.67 Under these criteria both research design and internal/external 
validity are taken into account when assessing the quality of an individual study. 
Each study is given a grade based on the traditional hierarchy of evidence (I 
[randomized controlled trial], II-I [controlled trial without randomization], II-2 
[cohort or case-control study], II-3 [multiple time-series with or without 
intervention, or dramatic results from an uncontrolled experiment], III [expert 
opinion, case reports, descriptive studies]). 
Additionally, grades are also assigned for internal and external validity based on a 
three-category rating system (good, fair, and poor). The study grade for internal 
validity is based on fulfillment of the following criteria: (1) comparable 
comparison; (2) equal, valid, and reliable measurement; (3) clear definition of the 
intervention; and ( 4) consideration of all important outcomes. Studies that meet 
all of these criteria are graded as "good". Studies that meet most of these criteria 
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are graded as "fair", and studies that meet few or none of these criteria, or those 
that have a fatal flaw, are graded as "poor". Similarly, the study grade for 
external validity is based on the fulfillment of the following criteria: (1) study 
population reflects the type and spectrum of patients that are likely to be seen by a 
general practioner, and (2) study procedures reflect actual clinical practice. 
Grades of "good," "fair," or "poor" are assigned in a similar fashion as for 
internal validity. 
Once the quality of each individual study has been assessed, the body of evidence 
as a whole is taken into account. At this level the internal and external validity of 
all the studies are considered in the aggregate, and the consistency and coherence 
of the evidence are each assigned a grade of"good," "fair," or "poor". 
Results 
Search Results: We summarize the results of our May 2004 literature review in 
Tables 8 and 9. Overall, we reviewed 5254 citations. 
Table 8: Summary of Literature Search Results 
Search Initial Number Number Number Number 
Strategy Number of Remaining Remaining Remaining Included in 
Articles After After After Systematic 
Identified Review of Review of Review of Review 
Article Titles Abstracts Articles 
I 1196 293 3 2 2 
2 3184 993 53 2 2 
3 813 12 I I I 
4 61 I I I I 
Total 5254 1299 58 6 6 
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Table 9: Articles Identified By Each Search Strategy 
Search Strategy Articles 
I "·"' 
2 7U, "IJ 
3 ,. 
4 " 
Total number of articles included in review 6 
3955 (75%) were clearly not relevant to the questions of interest. An additional 
1241 articles were excluded after careful review of the title and abstract. Detailed 
review of the remaining 58 articles excluded 52 articles. The most common 
reasons for exclusion were that the cited articles did not have an experimental 
design (i.e. they were reviews, editorials, and letters) (11 articles) or that they 
related to the development and validation of different risk scoring systems (23 
articles). A number of studies were also excluded because they either used risk 
scores as part of the eligibility criteria (for example, to limit a study population to 
high risk patients) or as an endpoint, but not as an intervention (18 articles). Six 
studies met our inclusion criteria and were included in our review. 
Of the six studies, four addressed whether routine calculation of a global risk 
score improves clinical outcomes (Table 10).69• 71 ' 73 The remaining two addressed 
the question of whether there are harms associated with risk calculation (Table 
11).68• 70 No studies directly addressed the effect of risk scores on patient 
adherence. All included studies were published after 1996. 
[Tables 10 and 11 are located at the end of the paper] 
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Of the four studies that addressed whether routine use of global risk scores is 
associated with clinical benefit, three were randomized controlled trials and one 
was a cohort study. Three took place in actual clinical settings, whereas a fourth 
study queried physicians using hypothetical patient scenarios. Three studies 
(those by Ramachandran, Lowensteyn, and Montgomery) took place in a general 
practice population, but the fourth (a study by Hall) was conducted in a Diabetes 
referral clinic. All four studies used some form of a Framingham-derived risk 
score. In two studies, risk scores were provided to the physician; in the other two, 
physicians were only given the tools for risk calculation. The number of patients 
and, more importantly, physicians included in each study varied widely, with the 
study by Hall being the smallest (6 physicians, 323 patients) and the study by 
Lowensteyn being the largest (253 physicians, 958 patients). As can be seen in 
Table 10, the primary endpoints of the four studies varied widely. 
Ofthe two studies that address the potential harms of using global risk scores, one 
is a non-blinded randomized controlled trial and one is a cohort study. Both 
studies used risk scores derived from epidemiologic databases other than 
Framingham (North wick Park Heart Study; 70 British Regional Heart Study and 
Dundee risk score68). However, in both instances the risk scores were presented 
in a categorical format (low, intermediate, high) similar to Framingham scores. 
Both included a relatively large number of patients, took place in a general 
practice population, and used questionnaires to assess their endpoints (Table 11). 
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As shown in Table 12, study quality for both studies on the benefits and harms of 
global risk calculation ranged from poor to fair. Three of the four studies 
addressing the clinical benefits of global risk scores received a rating of "I-fair" 
and one was rated as "II-2-poor". The two studies addressing harm were evenly 
split between the same ratings. Across all of the studies a major limitation in 
determining both the internal and external validity of each study was a significant 
lack of information about not only the study procedures, but also the baseline 
characteristics of both the physicians and the patients. This lack of information 
creates difficulty in assessing for important issues such as the adequacy of 
randomization, confounding, and selection bias. Additionally, among the 
randomized trials, blinding was only attempted in the studies by Hall and 
Lowensteyn, and in both instances it is unclear if it was successful. These issues 
are explored further in the discussions of each study. 
[Table 12 is located at the end of the paper] 
Does routine calculation of a global risk score improve clinical outcomes? 
Of the four studies assessing the benefit of global CHD risk calculation, the study 
by Hall and colleagues 73 provides the most direct evidence that risk calculation is 
associated with a change in physician prescribing habits. The only other study that 
addressed this outcome (Montgomery) examined as a secondary outcome?1 
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In the Hall study, six diabetologists saw 323 consecutive patients who were free 
of CVD and were alternately randomized to either an experimental or control 
group. For patients in the experimental group, physicians received 5-year CHD 
risk scores (New Zealand risk score) on the front of the chart. They received no 
such information for control patients. The primary outcomes were a documented 
change in treatment of diabetes, prescription rates of lipid lowering or 
antihypertensive drugs, or referral to a dietician. Overall, documentation of a risk 
score did not have an effect on physician prescribing habits; however, Physicians 
were more likely to prescribe a lipid lowering or anti-hypertensive drug to 
patients with a 5-year CHD risk >20% (52% ofthe patients (p<0.02). 
Several issues limit the usefulness of this study and result in it receiving a rating 
of "!-fair". Foremost among these is that almost no baseline data about patients 
or physicians was provided. This lack of information precludes knowing whether 
randomization was successful and leaves open the possibility of significant 
confounding. Adding to this is the fact that it is unclear whether the attempt at 
blinding the physicians and patients was successful. Furthermore, the endpoint is 
somewhat difficult to interpret because the only significant result came from 
subgroup analysis and no information was given as to the appropriateness of the 
changes in therapy. Although it can be argued that in high-risk patients increased 
prescribing of lipid-lowering and anti-hypertensive drugs is often the correct thing 
to do, from a decision-making standpoint, it would have been more informative to 
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determine whether risk scores led the physicians to make more appropriate (i.e. 
guideline-directed) decisions. 
The generalizability of the study is also questionable because of the small sample 
size and the type of patients included. Only six physicians from a single practice 
were included in the study, and it is difficult to know whether these physicians are 
truly representative most primary care clinicians. Furthermore, the population 
studied is not necessarily representative of the general primary care population. 
These patients all had diabetes, and by U.S. standards 87% of the patients would 
be considered as being at high risk (10-year CHD risk >20%). Despite this, the 
types of decisions being made by the physicians are reflective of typical primary 
care decisions. Similar endpoints were examined in the study by Montgomery 
and colleagues. 71 
In this study, patients' global risk and physicians' prescribing habits were 
examined in 27 general practices in the UK (comprised of 74 physicians and 11 
nurses) after physicians and nurses were randomized to receive one of three 
interventions: (I) a computer-based clinical decision support system plus a CHD 
risk chart (2) CHD risk chart alone (New Zealand risk chart), or (3) usual care. 
Both the computer-based system and the risk chart calculated identical estimates 
of 5-year CHD risk, the only difference being that the computer-based system 
presented the risk numerically and the chart presented it pictorially. From within 
each practice, 30 treated hypertensive patients were randomly selected for 
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invitation to participate in the study and a total of 614 patients attended a baseline 
screening visit and were enrolled in the study. Follow-up was completed at 12 
months. 
After adjustment for practice computer system and for baseline CHD risk, a 
similar proportion of patients in all three groups were still at high risk (5-year 
CHD risk 2:10%) after one year. Therefore it appeared that providing physicians 
with the tools to calculate global CHD risk did not improve patients CHD risk 
beyond usual care. Interestingly, however, analysis of secondary endpoints 
revealed that risk calculation was associated with lower mean systolic blood 
pressure at 12 months compared to usual care group (-4.6 mmHg). Patients in the 
chart only group were also more than two times as likely to be prescribed 
cardiovascular drugs than were patients in the other groups (p<0.01). Although 
these results did not adequately account for multiple comparisons and were 
attenuated in the computer group, they suggest that global risk calculation may 
affect physician prescribing and intermediate risk factor outcomes, but not enough 
to move an appreciable number of people across the high-risk cut-off. 
As with the studies by Hall, this study also received a quality rating of "I-fair". 
The primary reason for this rating is that the study was not blinded and that too 
few details were given regarding the study protocol. The former issue is 
particularly important because it leaves open significant room for confounding 
and bias on the part of both the physician and the patient. It is also problematic 
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that >25% of the patients already had CVD at baseline. Since global risk scores 
are meant only for primary prevention, their use in this population is questionable. 
The limited provision of data also limits the external validity of this study. No 
information is given as to the types of drugs (lipid lowering, antihypertensive, 
anti-anginal.. .. ) that were prescribed, and limited details are provided about 
exactly how the risk chart or computer system was used (by physician or nurse; 
before, during or after patient visit ... ). This lack of treatment and protocol details 
makes study interpretation difficult. Additionally, as with all the studies included 
in this review, these were generally high risk patients: the mean 5-year CHD risk 
at baseline was 18.5% (37% 10-year risk). Despite this, the overall control of risk 
factors at 12 months was surprisingly poor. For example, the mean systolic blood 
pressure in all three groups was still > 150 mrn Hg. This suggests that these study 
patients were not being treated to a similar standard as would currently be 
expected. 
Similar to the studies by Hall and Montgomery, the study by Lowensteyn72 also 
focused on physician calculation of global risk scores for patients. In this study, 
253 Canadian physicians were recruited from among 445 attendees at a 
continuing medical education meeting on CVD risk assessment. The physicians 
were randomized to either a profile group or a control group, and they were all 
instructed to emoll patients between the ages of30-74 who were free ofCVD and 
"in whom they thought a risk profile would be clinically useful." When a patient 
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was enrolled in the study, the physician and patient completed different parts of 
the enrollment form (data on risk factors, etc ... ) which was then mailed to the 
coordinating center. Profile physicians scheduled patients to come back in 2 
weeks for their risk profile results; control physicians did not. Control patients 
only received their risk profile if they returned for a follow-up visit in 3-6 months. 
At the 2 week follow-up, the profile group patients were told their 8-year CHD 
risk. Follow-up after that was at the discretion of the physicians and patients. 
The main hypothesis of the study was that being labeled as high risk at the initial 
visit would encourage physicians and patients to have a follow-up visit. 
Therefore, the main outcome measure was the likelihood of a high vs. low risk 
patient being seen at the 3-month follow-up. The difference in likelihood of 
follow-up between the two groups was considered to represent the effect of the 
risk profile. Secondary outcomes included changes in specific risk factor values 
between baseline and the 3-month follow-up. 
Overall, the likelihood of physicians reassessing high vs. low risk patients was 
significantly greater in the profile group, which suggested to the authors that 
calculation of a risk profile leads to increased follow-up of high risk patients. 
Additionally, after adjustment for baseline differences, the profile group patients 
demonstrated significantly greater reductions in lipid values(total cholesterol -
0.49 vs. -0.09 mmol/L) and calculated 8-yr CHD risk (-1.8% vs. -0.3%). There 
was not a significant difference for other risk factors. 
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The conclusions of this study must be viewed with criticism. First, although 253 
physicians were randomized into the study, only 51% of physicians (57% profile; 
39% control) actually enrolled patients in the study. The method of enrollment 
also raises the question of selection bias because physicians were instructed to 
enroll patients "in whom they thought a risk profile would be clinically useful." 
Combined with the broad inclusion criteria (age and freedom from CVD), these 
instructions allowed significant leeway in deciding which patients to recruit into 
the study. Since no data is given on patients who were screened but not enrolled 
it is impossible to rule out selection bias. This is true despite the fact that baseline 
patient characteristics were similar in both groups. 
More worrisome however, is the exceedingly high attrition rate among study 
patients. Although 958 patients were initially enrolled, only 50.6% of control and 
25.8% of profile group patients actually came back for follow-up. The disparity 
between groups appears to due to the study design which encouraged control 
patients to come back for follow-up because the results of the risk profile were 
withheld until that visit. This "encouragement" confounds the normal patient and 
physician motivation for scheduling (and for actually returning for) follow-up. 
The external validity of this study is hampered by the awkward study design, 
which does not mimic clinical practice. In fact, it is somewhat difficult to draw a 
parallel between the study scenario (patient provides risk factor information; 
38 of 102 
information is mailed to an outside agency; risk score is mailed back two weeks 
later) and what actually happens in the real-world (risk score is calculated and 
acted upon during a single clinic visit). 
In contrast to these studies, the final study addressing the clinical utility of global 
risk scores suggests that risk calculation may not be associated with a discernible 
benefit. This study, however, has important differences: it is a cohort study, 
which allows greater potential for confounding; it uses hypothetical patient 
scenarios to address the effects of risk calculation on clinical outcomes; and it has 
several flaws, which result in a poor quality rating. 
In this small study Ramachandran and colleagues69 mailed questionnaires to 200 
randomly selected general practioners (GPs) in the UK. Each questionnaire 
consisted of 20 patient case scenarios in which CVD risk factor information was 
given, and the GPs were asked to indicate what method they used to determine the 
patient's risk of CVD and whether they felt that lipid lowering therapy was 
indicated. The primary outcome was the proportion of correct responses based on 
the UK guidelines at that time which stated that lipid-lowering therapy is 
indicated in patients with a 1 0-year CHD risk> 30%. GPs were reminded of this 
guideline in the cover letter that accompanied the questionnaire. 
Only 61 physicians (30.5%) responded. Of these, 14 (26%) calculated a 10-year 
CHD risk score (Sheffield Table), 26 (48%) solely used clinical judgment to 
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gauge risk, and the remaining 21 (26%) used some combination of methods. 
Overall 62.1% of decisions were in accordance with the guideline; however, there 
was no difference in the appropriateness of decision-making between GPs who 
used clinical perception as the sole means of risk assessment and those who used 
the Sheffield table either on its own or in conjunction with other methods 
(p=0.21). 
While interesting, this study received a quality rating of "II-2-poor" for a variety 
of reasons. Foremost among these are the extremely low response rate and the 
fact that physicians were not randomized as to the method of risk determination 
used. Both of these introduce the possibility of significant confounding. 
Additionally, the low response rate suggests that the study likely does not have 
enough power to detect a significant difference in the primary endpoint. This is 
difficult to determine because no sample size calculations were reported. Lastly, 
since no information is given on physician characteristics it is impossible to 
determine if the physicians included in the study reflect the average general 
practioner. 
When these four studies are examined in aggregate the quality of the evidence 
supporting a clinical benefit to the routine use of global risk scores is poor to fair. 
Given that the no meaningful conclusions can be drawn from Ramachandran 
study, the overall evidence quality is pulled towards fair. However, this is 
counterbalanced by the fact that of the remaining three studies, only the small 
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study by Hall directly addresses the question of interest. While the studies by 
Lowensteyn and Montgomery both provide some evidence of a benefit associated 
with the use of global risk scores, neither addresses the routine use of risk scores 
as they would be expected to be used in practice. Additionally the lack of 
treatment details in all three studies creates difficulty in establishing a fully 
credible linkage between the use of risk scores and the modest clinical benefits 
seen in each study. Additional difficulty in drawing a conclusion is introduced 
because the Hall study, which represents the most direct evidence, only included 
six physicians. In terms of physician sample size this is significantly outweighed 
by the Lowensteyn and Montgomery studies. 
Are there harms associated with screening nsing global CHD risk scores? 
Two studies directly address whether CVD screening using global risk scores is 
associated with adverse psychological outcomes. Both studies suggest that there 
is not any significant harm. However, both are marked by several flaws which 
limit their validity. 
Connelly70 performed a prospective cohort study of 5772 men in which all 
participants underwent CHD screening and were informed of their level of CHD 
risk based on an algorithm derived from the Northwick Park Heart Study. The 
men were not told their risk level at the initial screening; rather they were later 
sent a letter that informed them of their personal risk for CHD (categorized as 
low, moderate, or high). Men deemed to be at "high" risk were seen back for a 
follow-up appointment during which they were able to discuss the results. The 
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letters sent to men deemed to be at "moderate" risk included general advice about 
the particular risk factor that was elevated; however no follow-up appointment 
was offered. The "low" risk men were simply sent a letter stating that they did 
not have any special risk for CHD. 
Psychological symptoms in all ofthe men were assessed at the baseline screening, 
at the time that they were informed of their risk level, and again at three months. 
Overall, men who were labeled as being at either "high" or "low" risk showed a 
decrease in their psychological symptoms after labeling. Interestingly, the men 
who were labeled as "moderate" risk actually had an increase in psychological 
symptoms. Taken together, this result appears to suggest the intuitive conclusion 
that if information about elevated risk is not accompanied by appropriate support, 
there may some degree of increased anxiety among patients. 
This study received a quality rating of "II-2-fair" based on several factors. The 
primary internal validity issues were that the study was uncontrolled and not 
blinded. Additionally, not enough details were provided about the risk score and 
what went on at the screening and follow-up visits. When coupled with a 25% 
drop-out rate, these issues raise questions about the strength of the evidence 
provided by the study that even the large sample size does not completely 
outweigh. The generalizability of the study is hampered by a lack of details about 
the interventions and by the nature and clinical significance of the "psychological 
symptoms" experienced by the patients. 
42 of 102 
Despite being a randomized controlled trial, the study addressing harms by 
Marteau and colleagues68 is fraught with such a substantial omission of 
information that it is very difficult to use in drawing conclusions. This study 
randomized approximately 3000 couples to a screening or a control group. The 
screening group couples underwent psychological and CHD screening, including 
an estimate of their global CHD risk. They were then counseled on ways to 
reduce CHD risk, and they were offered follow-up at a frequency commensurate 
with their level of risk (more frequent follow-up for higher risk patients). Control 
patients did not undergo any screening until the one year mark, at which time they 
underwent the same procedure as the screening group. The primary outcome was 
a comparison of the perceptions of health, the risk of suffering a heart attack, and 
the ability to reduce that risk in the intervention and the control groups at 1 year. 
Overall, the study results suggest that participation in a screening program 
including calculation of a CHD risk score was not associated with adverse 
concerns about health, but that it may be associated with a sense of less control 
over one's own personal risk. 
Exceedingly few details were provided regarding several key issues, including the 
screening and enrollment process, randomization, attempts at blinding, baseline 
patient characteristics, content of follow-up visits, and treatments that were 
undertaken. Additionally, the clinical relevance of the questionnaire measures is 
unclear. Taken as a whole, these omissions make it impossible to rule-out a 
43 of 102 
variety of sources of bias and confounding. Therefore the study received a quality 
rating of"I-poor". 
In aggregate, there is poor to fair evidence that global risk scores are not 
associated with significant psychological harms. The large sample size of the 
Connelly study bolsters the "fair" rating, however given that it is only a single 
study it is difficult to draw any firm conclusions. 
Discussion 
Despite calls for widespread use of global CHD risk scores as a clinical screening 
tool there is a paucity of literature supporting the numerous theoretical benefits 
associated with such screening. The majority of the literature on global risk 
scores currently relates to the development and validation of different risk scoring 
systems. This review highlights the fact that not much research has been done to 
elucidate the actual clinical benefits that can be expected if clinicians adopt global 
CHD risk scores into their everyday practice. 
Based on the available studies reviewed in this paper, there is fair to poor 
evidence that the routine use of global CHD risk scores may be associated with an 
increase in the prescribing of cardiovascular drugs to high risk patients and 
possibly with improved control of blood pressure and cholesterol levels. 
However, even excluding the one poor quality study, the small number of studies 
with disparate outcomes and the relatively small number of physicians included in 
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these studies precludes definitive conclusion about the effects of global risk 
calculation on physician prescribing habits and any subsequent reduction in 
patient risk factors and global CHD risk .. 
Indirect support for the clinical benefit of global CHD risk scores comes from two 
studies which were not included because they did not meet all of the inclusion 
criteria. Both studies examined whether global CHD risk estimation, in 
conjunction with a broader screening and/or behavioral intervention is associated 
with clinically apparent changes in CHD risk factors. Both found some evidence 
of benefit. 
In 1985, Lovibond and colleagues74 performed a small trial in which 75 patients 
deemed to be at high risk of CHD were randomized to one of three behavioral 
interventions: (1) maximal behavioral treatment, (2) extended behavioral 
treatment, or (3) basic behavioral treatment. All three interventions involved 
attendance at both group and individual counseling sessions for 6 months and all 
were designed so as to attempt simultaneous correction of multiple CHD risk 
factors through intensive multi-faceted lifestyle modification. As a part of this 
larger program, groups 1 and 2 were also provided with information about their 5-
year risk of CHD. Group 3 was not. 
After 12 months all three interventions were found to be associated with 
significant beneficial changes in weight, blood pressure, aerobic capacity, 
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cholesterol, smoking status, and overall calculated CHD risk. The groups that 
received information about global CHD risk appeared to have a slightly greater 
benefit, thus suggesting that provision of global CHD risk information was a 
beneficial component of the overall program. 
In a different study, Engberg and colleagues 75 investigated the effect of a general 
health screening on the cardiovascular risk profile of a randomly selected 
population in a small rural county in Denmark. In this randomized controlled 
trial, 1507 residents of the county who were between the ages of 30 and 49 years 
were randomized to one of three arms: (1) a control group that received no health 
screenings, (2) an intervention group that received two health screenings, and (3) 
an intervention group that received two screenings and a 45-minute follow-up 
consultation aunually for five years. The health screenings were performed by a 
laboratory assistant (not a physician) and included calculation of a CVD risk 
score. Each person received personal written feedback from his/her doctor within 
a few weeks after the screening session. If values for CVD risk factors fell 
outside the normal range advice about lifestyle modification was given. If CVD 
risk was calculated as "high" the letter suggested that the person should follow-up 
with the doctor. Educational pamphlets were also sent to all participants. The 
health discussion was a 45-minute consultation with the physician at the end of 
which goals were set for lifestyle modification. 
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After five years, there was a small but statistically significant difference in the 
mean CVD risk score, body mass index, and cholesterol levels in the intervention 
groups as compared to the control group. The benefit appeared to be greater 
among smokers and overweight patients. Additionally, there was also a lower 
prevalence of patients deemed to be at "high" risk in the intervention groups. 
This again appears to suggest a modest benefit to global CHD risk scores when 
used in conjunction with a larger screening and behavior modification program. 
Although both of these studies are of interest, they were not included in the 
formal review because the risk score itself was not the primary intervention and 
because they both had a greater focus on patient use of risk information rather 
than on physician use of that information. Additionally, their direct applicability 
to everyday clinical practice is questionable. In both cases it is impossible to 
tease out the effect of global CHD risk scoring from the rest of the intensive 
intervention, and neither study addresses whether routine calculation of global 
risk scores by physicians is clinically beneficial. Therefore, at best, these studies 
provide a modicum of additional indirect support for the idea that global risk 
scores can be helpful. 
An issue which was not addressed by included studies is whether patients were 
provided with their global risk scores and whether this altered patient behavior. 
Indirect evidence is also limited, with the only study that marginally addresses 
this issue being by another Montgomery and colleagues. 76 
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In this small study they found that when CHD risk scores were incorporated as 
part of an intensive decision-analysis session, newly diagnosed hypertensive 
patients reported less decisional conflict about whether to start an 
antihypertensive drug than did patients who only received an informational video 
and leaflet. The patients who were told their risk score and who underwent 
intensive decision-analysis counseling reported less decisional conflict about 
starting anti-hypertensive treatment. Unfortunately, as with the studies by 
Lovibond and Engberg, the study design makes it is impossible to distinguish the 
separate effect of CHD risk scoring apart from the overall intervention. 
Additionally, at three months there was no difference in the number of patients 
who actually wound up taking medication, which suggests that the reduced 
decisional conflict did not translate into a clinically meaningful difference. 
Given that only one of the two studies addressing the psychological harms 
associated with global CHD risk screening was judged to be of at least fair 
quality, it is not possible to come to any final conclusion about the balance of 
benefits and harms associated with risk calculation. The study by Connelly does 
suggest that there are no discemable psychological harms when global CHD risk 
screening is accompanied by appropriate information and support. As noted, 
however, the quality of this study and the fact that it is only a single, albeit large, 
study limits the conclusions that can be drawn. 
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One interesting facet to the question of harm is that in order for psychological 
harm to be plausibly related to the use of global risk scores, patients must be told 
of their calculated risk. Of the studies assessing clinical benefits, only the 
Lowensteyn study specifically stated that patients were told their risk score. The 
other studies do not provide enough information to determine if patients were told 
or not. The Lovibond and Engberg studies also informed patients of risk, 
however no harm-related endpoints were collected. The curious lack of attention 
to possible harms associated with the use of global risk scores suggests that the 
investigators in all ofthese studies assumed that no possible harm could arise. As 
we have shown, there is very little evidence to either support or refute this belief. 
Overall, the paucity of evidence makes it is impossible to reach any broad 
conclusions about the true clinical benefits or harms associated with the use of 
global CHD risk scores. The evidence that does exist appears to point in the 
direction of a modest benefit without any discernible harm. Importantly, there are 
no studies that demonstrate a benefit in terms of hard outcomes. Despite this, the 
increase in prescribing of cardiovascular drugs suggests that the routine use of 
global risk scores may lead to a tangible clinical benefit. Although an 
indiscriminant increase in prescribing would not be helpful, increased prescribing 
of anti-hypertensive and lipid-lowering drugs is often indicated in patients at 
intermediate to high risk of CVD. As previously reviewed, there is currently a 
gross underutilization of such evidence-based therapies, and if global risk scores 
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can be shown to improve this situation it would be an important reason to use 
them. 
Furthermore, the small improvements in lipid levels and blood pressure seen in 
two of the studies may be important. On a population level these changes, which 
likely reflect the increased use of risk-modifying medications, have the potential 
to benefit a significant number of patients. 
As noted in the introduction, risk stratification is requisite for achieving a 
favorable balance between the potential benefits and harms of therapies aimed at 
reducing CVD risk. Given that both clinicians and patients have difficult 
estimating risk, as well as the theoretical benefits and the fact that global risk 
scores are simple, readily available in the clinic, non-invasive, inexpensive, and 
well-validated it is important that the medical community better understand the 
their use. 
This review highlights the fact that very little is actually known about the best 
manner in which to incorporate global CHD risk scoring into everyday practice. 
Further research is needed to better elucidate the true benefits, best target 
population, and most appropriate setting for the use of global risk scores. 
Additionally, it is important to delineate the mechanism of any benefits that are 
proven. Only with a thorough understanding how risk scores affect clinical 
decision-making can we hope to appropriately integrate them into practice. 
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Future studies will ideally address these issues in a more direct manner than has 
been used in the studies described here. Prospective trials in which global risk is 
calculated in a systematic and standardized fashion are most likely to provide 
useful information. Although it is unlikely that any trials will be large enough to 
address hard endpoints, smaller studies addressing issues of physician decision-
making and adherence with guidelines, patient adherence with therapies, and 
control of blood pressure, lipid levels, and other risk factors are quite feasible and 
would provide much useful information. Importantly, any future studies must 
also carefully collect data on treatments that are undertaken (or foregone) on the 
basis of risk score information, as this data is critical to having a full 
understanding of the dynamics of global risk score information in practice. 
Lastly, the issue of harm cannot be ignored. Although significant harm seems 
unlikely, the current evidence is insufficient to reach that conclusion. Aside from 
the potential for psychological harm associated with labeling, there is also a 
possibility that use of risk scores could be associated with an increase in 
inappropriate prescribing or even with under utilization of therapies if the patient 
and clinician are falsely reassured. Any future research should carefully 
document these issues. Clinicians should also be aware that the meager evidence 
that is currently available suggests that CVD risk score should be accompanied by 
an appropriate amount of explanation and support. What is "appropriate" likely 
depends on the level of risk and remains to be determined in future studies. 
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This analysis has several limitations. Although a relatively exhaustive literature 
search was attempted, there remains the possibility that relevant literature may not 
have been located. The questions posed by this review lend themselves to a 
variety of research designs by investigators in different disciplines, and as found 
in this search, no one search strategy was able to identify all of the relevant 
articles. Although it was felt that the current search likely identified the most 
relevant articles and that a more extensive search would likely provide a very low 
yield, it is possible that some studies may have been missed. A similar problem is 
posed by the limitation of the search to the English language literature and by the 
fact that no attempts were made to contact experts in this field outside of the 
University of North Carolina to query them about literature that they might be 
aware of. Finally, there is no way to assess for publication bias. 
Global CHD risk scores represent a potentially useful addition the clinician's 
armamentarium. Given the burden of CVD in our society and the significant 
amount of work that needs to be done to improve our CVD prevention efforts, 
global risk scores may well be an important additional screening tool. If future 
research continues to bear out their usefulness, their ease of use and low 
opportunity cost will cause them to be counted as a significant addition to 
preventive medicine in the U.S. 
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The Effect of Global CHD Risk Scores on 
Physician Decisions Regarding the Primary 
Prevention of Cardiovascular Disease: 
Preliminary Results 
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Background 
Physicians often do not accurately estimate a patient's risk for future 
cardiovascular events.26-32 This is potentially problematic because the assessment 
of global coronary heart disease (CHD) risk has been integrated into multiple 
guidelines for the primary prevention of CHD1-3. Estimations of risk can be 
improved by the use of risk calculations based on data from the Framingham 
cohort, 18• 25• 36 and these calculations are relatively simple to perform using either 
hand-scored sheets or readily available calculators for personal digital assistants 
(PDAs) and computers39. Despite the theoretical benefit of risk calculation, 
however, there is relatively little data on whether the routine use of such 
calculations actually translates into improved clinical outcomes. In particular, 
there is little known about how knowledge of a patient's calculated 1 0-year risk 
affects a physician's perception of a patient's risk and whether that in turn 
translates into improved adherence with published guidelines for the primary 
prevention ofCHD. 
The purpose of this study is to determine whether clinicians make better CHD 
prevention decisions when they interpret risk factor information in the context of 
a calculated global risk score than when they view risk factor information alone. 
The methods and preliminary results of this study are briefly presented here. 
Methods 
Study Design: A multi-center, randomized, single-blinded study. 
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Setting: Two academic medical centers in North Carolina: The University of 
North Carolina (UN C) and Duke University Medical Center (DUMC). 
Subjects: Convenience sample of Internal Medicine, Medicine/Pediatrics, and 
Family Medicine residents who were recruited into the study during one of their 
regularly scheduled educational conferences. 
Inclusion Criteria: Participants had to be Internal Medicine, 
Medicine/Pediatrics, or Family Medicine residents at UNC or DUMC. 
Exclusion Criteria: (1) Failure to consent to participate in the study; (2) Non-
resident status (medical student, attending physician, or physician extender) 
Intervention: The study intervention consisted of a questionnaire containing ten 
clinical case scenarios and several additional questions pertaining to the 
participant's attitude towards CHD risk scores. The patient scenarios were crafted 
to explore physician's knowledge about preventive guidelines for CHD, including 
the recommended thresholds for prescription of aspirin, hypertension medications, 
and cholesterol lowering medications. Additionally, the order of the scenarios 
was varied among three different sequences in order to avoid bias from any 
ordering effects. 
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Participants were randomly assigned into two groups: Group 1, the intervention 
group, was given the calculated Framingham risk score for each patient scenario. 
Group 2, the control group, was not given the risk score, nor were they allowed to 
calculate the score on their own. A computerized program was used to generate 
the randomization scheme. 
Table 13 lists the ten cases that were presented on the questionnaires along with 
the rationale for including the case and whether guidelines indicated that aspirin, 
lipid-lowering therapy, or anti-hypertensive therapy is indicated by current 
guidelines. Appendix 3 shows an example of how the cases were presented. For 
each case, subjects were asked to estimate the patient's short-term CHD risk using 
traditional risk categories (low, intermediate, high). Group 1 was given a numeric 
risk estimate that could be used as a basis for selecting a categorical risk level, 
and group 2 had to both select a risk category and make a numerical estimate of 
the patient's risk. Following this, subjects were asked whether the patient met 
criteria for the metabolic syndrome, and then they were asked whether aspirin, 
lipid-lowering therapy, or anti-hypertensive therapy were indicated for the patient. 
They were also asked if any additional diagnostic tests were indicated. 
[Table 13 is located at the end of the paper] 
Assessment: As noted, participants were asked to state their recommendations for 
preventive interventions in each scenario. Questions formatted as Likert-type 
56 of 102 
scales were used to assess their level of comfort with the guidelines for CHD 
prevention and their general impressions regarding the utility of Framingham-
based global risk scores. Post-graduate year and type of residency program were 
the only demographic information collected. 
Blinding: The investigators were blinded to group assigmnent until after the 
questionnaire had been completed. Subjects were blinded to study design and 
they were not told that some questionnaires include risk scores and others did not. 
Endpoints: 
Primarv Endpoint: 
The pre-specified primary endpoint was a comparison of the mean number of 
correct preventive recommendations in each group. "Correct" answers are those 
that are in compliance with the recommendations set forth in the JNC-VII, 11 
NCEP-ATPne and USPSTF/· 77 guidelines. For each participant an overall 
questionnaire score was calculated using the following formula: Overall score = 
number of correct recommendations regarding aspirin, cholesterol medication, 
and antihypertensive medication/Total number of possible recommendations) x 
I 00. Since each questionnaire had ten cases and subjects were required to 
recommend for or against preventive intervention in three domains (aspirin 
chemoprophylaxis, cholesterol-lowering medication, and antihypertensive 
medication) in each case, a score of I 00% indicates that the subject made 
"correct" recommendations for all 30 questions. Scores for the individual 
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guideline areas were calculated in the same manner (denominator for these 
calculations was 1 0). 
Secondary Endpoints: 
Secondary endpoints included a comparison between Groups 1 and 2 for each of 
the following: 
The proportion of subjects who correctly make all of the 
appropriate recommendations for each of the individual cases. 
The proportion of subjects who recommend appropriate lipid-
lowering therapy for all patients who need it. 
The proportion of subjects who appropriately recommend aspirin 
use in all those for whom it is indicated. 
The proportion of subjects who appropriately recommend 
cessation of tobacco use in all those for whom it is indicated. 
The proportion of subjects who correctly identify ::;130/80 
mmHg as the goal blood pressure in diabetic patients. 
The proportion of subjects who correctly categorize each 
patient's 10-year CHD risk on a scale oflow-intermediate-high. 
The proportion of subjects who correctly recognize patients with 
the metabolic syndrome. l 
The proportion of subjects that recommend hs-CRP testing in 
accordance with AHA/CDC recommendations.49 
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The proportion of subjects who recommend a variety of other 
risk-stratification tests including coronary electron-beam 
computed tomography, exercise treadmill testing, and ankle-
brachial index. 
An assessment of resident attitudes towards CHD risk scores. 
Statistical Analysis: 
Descriptive statistics were used to describe participant's baseline characteristics 
and perceptions of CHD risk scores. For the primary endpoint, the mean number 
of correct preventive recommendations in each group was compared using at-test. 
The proportion of correct responses for the categorical endpoints (as outlined in 
the secondary endpoints section) in each group was compared using a Chi-square 
test. An alpha level of 0.05 was considered statistically significant. 
Sample Size Calculation: 
The literature suggests that 35-58% of treatments are prescribed in accordance 
with guidelines.20-23 Therefore it was assumed that the control group would 
reflect this pattern and would have an adherence with guidelines (as measured by 
mean questionnaire score) of approximately 45%. We estimated that an increase 
of ~15% would be clinically meaningful. No data on the standard deviation for 
questionnaire scores is available; however a small study examining the effect of 
documented risk scores on physician prescribing practices found a standard 
deviation (SD) of -30% for the mean change in level of prescribing of different 
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medication classes.78 Accepting a two-sided alpha level of 0.05 and power of 
0.80, we estimate that a sample size of 126 (63 per group) is required to detect a 
difference in the primary endpoint between the groups. (Calculation performed 
with Stata 8.0 for Windows; Stata Corporation, College Station, TX) 
' b 
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Results 
To date 71 subjects have taken part in the study. The baseline characteristics of 
the subjects are shown in Table 14. The only significant difference between the 
groups was that the subjects in Group 2 reported a slightly higher comfort level 
with the guidelines for using aspirin in primary prevention. 
T bl 14 B r S b" t Ch a e : ase me UJ]eC t . ti arac ens cs 
Group 1 Group2 
(Risk Score) (No Risk Score) 
N=38 N=33 
Site 
UNC 12 (31.6) 11 (33.3) 
Duke 26 (68.4) 22 (66.7) 
Type of Residency (N [%]) 
Internal Medicine 37 (97.4) 31 (94.0) 
Med/Peds I (2.6) 2 (6.0) 
Family Medicine 0 0 
Post-Graduate Year (N [%]) 
I 16 (42.1) 12 (36.4) 
2 9 (23.7) 9 (27.3) 
3 II (29.0) 10 (30.3) 
4 2 (5.3) 2 (6.1) 
Other 0 0 
Level of Comfort with 
Cholesterol Guidelines (N [%]) 
Very Comfortable 10 (26.3) 16 (48.5) 
Somewhat Comfortable 26 (68.4) 13 (39.4) 
Somewhat Uncomfortable I (2.6) 4 (12.1) 
Very Uncomfortable I (2.6) 0 
Level of Comfort with Aspirin 
Guidelines (N [%]) 
Very Comfortable 8 (21.1) 13 (39.4) 
Somewhat Comfortable 25 (65.8) 17(51.5) 
Somewhat Uncomfortable 4 (10.5) 3 (9.1) 
Very Uncomfortable I (2.6) 0 
Level of Comfort with 
Hypertension Guidelines 
(N [%]) 
Very Comfortable 13 (34.2) 16 (48.5) 
Somewhat Comfortable 22 (57.9) 14 (42.4) 
Somewhat Uncomfortable 2 (5.3) 2 (6.1) 
Very Uncomfortable I (2.6) I (3.0) 
P S 0.05 for all between group comparisons except for comfort level 
with aspirin guidelines, for which P = 0.04 
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Overall 
N=71 
23 (32.4) 
48 (67.6) 
68 (95.8) 
3 (4.2) 
0 
28 (39.4) 
18 (25.4) 
21 (29.6) 
4 (5.6) 
0 
26 (36.6) 
39 (54.9) 
5 (7.0) 
I (1.4) 
21 (29.6) 
42 (59.2) 
7 (9.9) 
I (1.4) 
29 (40.9) 
36 (50.7) 
4 (5.6) 
2 (2.8) 
Risk Estimation 
Subjects in both groups had difficulty estimating the categorical short-term CHD 
risk of the case patients (Table 15). Overall, the subjects were only correct 56± 
18% of the time. There was a trend toward more accurate risk assessment in the 
group that was given a risk score (64 ± 13% versus 47 ± 27%), but the difference 
did not reach statistical significance (p = 0.1 0). 
[Table 15 is located at the end of the paper] 
In addition to difficulty with risk estimation, the subjects were inconsistent in the 
way that they categorized CHD risk (Table 16). Specifically, the categorical risk 
level (i.e. low, moderate, high risk) selected by the subjects only correlated with 
the numeric risk estimate 64 ± 11% of the time. There was no difference between 
the two groups as to the correct matching of categorical and numeric risk 
estimates (p = 0.22). 
[Table 16 is located at the end of the paper] 
Appropriateness of Decisions 
Overall, subjects made guideline-appropriate decisions about the three risk-
reducing interventions 72% of the time (Table 17). There was a trend toward a 
greater proportion of correct answers in patients who received global CHD risk 
scores, however this trend did not reach statistical significance. When we 
examined each intervention separately, the only significant difference between the 
groups was seen with decisions about aspirin therapy. The subjects who received 
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global CHD risk scores were significantly more likely to make correct decisions 
about aspirin therapy than were the subjects who did not receive risk scores 
(Table 17). 
T bl 17 P a e : f ropor Ion o fG 'd I' A . t R UI e me- lppropna e d f ecommen a Ions 
Endpoint Overall Group I Gronp2 
(Risk Score) (No Risk Score) 
N=71 N=38 N=33 
Overall Score* 71.7 (8.8) 73.1 (7.5) 70.2 (10.0)) 
Aspirin Score* 68.2 (15.4) 71.8 (16.0) 63.9 (13.7) 
Cholesterol Score* 68.5 (12.5) 68.7 (13.0) 68.2 (12.1) 
Hypertension Score* 78.6 (18.9) 78.7 (18.0) 78.5 (20.2) 
All data are presented as mean (SO). 
• Overall score = (# of correct recommendations regarding aspmn, 
cholesterol medication, and anti-hypertensive medication/Total number of 
possible recommendations) x 100. Each questionnaire had ten cases and 
subjects were required to recommend for or against aspirin 
chemoprophylaxis, cholesterol-lowering medication, and anti-
hypertensive medication in each case. A score of 1 00% indicates that 
subjects made correct (guideline-directed) recommendations for all 30 
questions. Scores for the individual guideline areas were calculated in the 
same manner (denominator for these calculations was 10). 
Pvalue 
0.174 
0.030 
0.867 
0.965 
For all cases save #1 and #2, less than 50% of subjects were able to make correct 
decisions about all three CHD preventive interventions (i.e aspirin, blood pressure 
lowering, cholesterol lowering) simultaneously (Table 18). Overall, provision of 
a risk score was not associated with an increased likelihood of making correct (p 
= 0.91). 
[Table 18 is located at the end of the paper] 
Tables 19-21 provide a case by case listing of the proportion of subjects who 
made correct decisions for each CHD preventive intervention. For the majority of 
cases there was no difference between those who received risk scores and those 
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who did not. However, significant differences were seen for cases 8 (aspirin and 
lipid-lowering therapy) and 9 (aspirin). 
[Tables 19-21 are located at the end ofthe paper] 
Identification of the Metabolic Syndrome 
Three cases met NCEP-ATP III criteria for the diagnosis of the metabolic 
syndrome. Only 23% of subjects correctly identified these cases (Table 22). 
There was no difference between groups 1 and 2 (p = 0.91). 
T bl 22 ld 'fi a e : ent1 !CatiOn o f h M t e etabo li s d c yn rome 
Case Overall Group 1 Group 2 
(Risk Score) (No Risk Score) 
2 35.7 39.5 31.3 
3 8.6 10.8 6.1 
7 25.7 21.6 30.3 
All values represent the proportiOn of subjects who correctly 
identified the metabolic syndrome in the patient's who met NCEP-
A TP III criteria for the metabolic syndrome. 
Additional Diagnostic Testing 
P value 
0.474 
0.479 
0.407 
Only a minority of respondents indicated that additional diagnostic testing was 
necessary prior to making treatment decisions. Table 23 lists the proportion of 
subjects that indicated that further testing was necessary for each case. 
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Table 23: 
Case# CRP 
(Risk Level) 
Attitudes Towards CHD Risk Scores 
Only 21 respondents (30%) correctly identified 2:20% as the cut-offvalue for high 
short-term risk. Thirty respondents (44%) thought that the risk cut off was lower, 
and 18 respondents (26.1 %) thought it was higher (10-year risk 2:25-50%). Only 
26 (37%) of respondents correctly identified :SlO% as the cut-offvalue for low 
short-term risk. Forty-two respondents (60%) thought the cut-offwas lower, and 
two respondents (3%) thought the cut-off was higher. 
23% of respondents reported that they never calculate a 10-year CHD risk score 
when making decisions about CHD prevention. Of the 77% of respondents who 
reported that they do calculate a risk score, only 1% "always" do so. Most 
respondents reported calculating a risk score "sometimes" ( 62%) or "most of the 
time" (13%). 
Of those respondents who do calculate a risk score, the majority ( 69%) reported 
that they used a personal digital assistant (PDA) to do so. The rest either used a 
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computer/website (22%) or a paper chart (9% ). When asked whether the 
calculation of a risk score had ever changed their initial perception of a patient's 
CHD risk, 98% of respondents replied "sometimes" (80%) or "often" (18%). The 
majority (72%) also reported sharing the risk score with the patient. 
When asked whether they agreed with the statement "I find CHD risk calculation 
useful", 95% of respondents either agreed or strongly agreed. Similarly, 90% of 
respondents either agreed or strongly agreed that CHD risk calculation can help 
them to make better decisions about whether or not to recommend therapies to r 
prevent CHD events. However, when asked whether they felt that CHD risk 
calculation saves time, only 44% of respondents agreed. 
Among those respondents who do not routinely calculate a CHD risk score the 
most common reasons for not doing so are that they already document CHD risk 
factors and do not feel that calculating a risk score provides additional useful 
information (13%), it takes too long (21 %), lack of convenient access to a risk 
score calculator (17%), lack offamiliarity with risk scores (8%), and a belief that 
the calculated score is not valid for their patient population (1 %). 
Discussion 
As with previous studies, the participants in this study demonstrated considerable 
difficulty with CHD risk estimation. In fact, whether or not a global risk score 
was provided subjects did little better than chance when they attempted to 
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estimate categorical CHD risk. It is particularly interesting that there was a 
demonstrable lack of knowledge as to the definitions of low, intermediate, and 
high risk. When asked about the cut-offs for each of the risk levels, only 
approximately one third of the subjects were able to correctly identify the 
traditionally accepted cut-offs. This confusion about risk levels was also 
apparent in the fact that subjects often did not correctly match their numeric risk 
estimate with the correct categorical risk level. For example, a subject might state 
that a given patient was at "high" CHD risk, but then would provide a numeric 
risk estimate well below 20%. This confusion was also true whether or not a risk 
score was provided and was independent of the patient's true level of risk. 
Since an understanding of the definitions of the different levels of short-term 
CHD risk is a prerequisite for proper interpretation of a global CHD risk score, it 
is not surprising that a greater difference was not seen between the groups in 
terms of the guideline-appropriateness of participant decisions. The fact that 
participants who received global risk scores did just as poorly at estimating 
categorical level of risk as participants who did not receive risk scores, suggests 
that much of the information provided by the global risk score was not apparent to 
the participants. In theory, if participants understood the definitions of the risk 
categories, 100% of the subjects who received global CHD risk information 
should have made correct categorical risk estimates. 
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This apparent lack of understanding of global risk score information creates 
difficulty in interpreting the preliminary results of this study. Although the use of 
global CHD risk scores appears to be associated with better decisions about 
aspirin chemoprophylaxis and a trend towards overall increased appropriateness 
of decisions about interventions to prevent CHD, the magnitude of this benefit is 
likely masked by the participant's seeming inability to correctly interpret the risk 
score information. 
Of the three preventive interventions explored in this study, the guidelines for 
aspirin therapy are the most dependent on CHD risk assessment, and therefore it 
is not surprising that the effect of risk score calculation is most prominent for this 
domain. However, the current NCEP-ATP ne guidelines stipulate that risk 
calculation should be a part of the evaluation of all patients with 2':2 risk factors, 
and therefore the global risk score should have been useful in seven of the ten 
cases. In particular, in both cases #2 and #4 the global risk score suggests that a 
lower LDL-C goal should be targeted. Despite this, there was no effect apparent 
in the group that was provided with a risk score. This, along with the fact that 
subjects often recommended aspirin in cases where it was clearly not indicated by 
the risk score (cases #5, 7, 9, and 10) also suggests a general lack offami1iarity or 
understanding of current guidelines for the primary prevention of CHD. This is 
apparent despite the fact that the majority of participants indicated that they felt 
"somewhat" or "very" comfortable with these guidelines. Given the general lack 
of understanding of how to interpret risk score information, it is somewhat 
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surprising that 77% of respondents reported calculating a risk score on at least 
some occasions, and that >90% of those who do so find CHD risk calculation 
useful. 
This lack of full familiarity with guidelines is also apparent in the poor 
identification of the metabolic syndrome and in the way that additional diagnostic 
tests were ordered. Although three of the cases met the NCEP-ATP III criteria for 
the metabolic syndrome, the majority of subjects were not able to identify these 
cases. Additionally, although only a minority of subjects requested additional 
diagnostic testing, the circumstances in which the tests were ordered were often 
inconsistent. For example, although the AHA/CDC guideline49 only suggests hs-
CRP testing for individuals at intermediate risk, subjects were equally likely to 
order it for high and low risk patients. 
Given that only 71 physicians have taken part so far, no firm conclusions can yet 
be drawn from this data. Despite this, the trends that have been briefly discussed 
above do suggest that future studies that aim to examine the usefulness of global 
risk scores may benefit from providing participants with greater background 
information about current guidelines and the interpretation of risk scores. As with 
any tool, it is difficult to study the potential benefits of global risk scores if the 
participants in the study do not fully grasp how to use them. 
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Figure 1: 
The Continuum of Cardiovascular Disease Risk and Prevention 
No Risk Factors Accumulation of Risk Factors L .... 
~ ~ Risk For CVD Events High 
.... Subclinical ~ Atherosclerosis Detected Advanced Atherosclerosis No atherosclerosis ~ 
Primordial ~ 
Prevention 
-
Atherosclerosis Prior to CVD Events CVD Events 
Primary 
Prevention 
L 
... Secondary 
Prevention 
L 
... Tertiary 
Prevention 
Healthy Diet Continue throughout Patient's Lifetime 
Physical Activity 
Tobacco-use Prevention 
r 
Aspirin for those with >6% 1 a-year CHD risk --
Tobacco-use cessation 
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Table 2: Estimates of benefits and harms of aspirin therapy given for 5 years to 
1,000 individuals with various levels of baseline risk for coronary heart disease* 
Benefits and harms Baseline rillk for coronary heart disease ov<!r 5 yearst . .. 
1% 3% . 
. 
5% 
Total mortality No effect No effect No effect 
CHDeventst 1-4 avoided 4-12 avoided 6-20 avoided 
Hemorrhagic strokes•• 0•2 caueOO · 0-2 caused 0-2caused 
. 
Major gastrointestinal 2-4 caused 2·4 caused 2-4 caused 
bleeding events++ 
. 
Adapted from: Aspirin for the primary prevention of cardiovascular events: recommendation aod 
rationale. Ann Intern Med. Jan 15 2002; 136(2):157-160. 
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Table 4: Relative Risk of CHD Events Associated with the Various CHD risk factors 
Risk Factor Men Women 
RR 95%CI RR 95%CI 
Age,y 1.05 1.04-1.06 1.04 1.03-1.06 
BP 
normal I I 
High nl 1.32 0.98-1.78 1.34 0.88-2.05 
Stage 1 1.73 1.32-2.26 1.75 1.21-2.54 
Stal!e 2 1.92 1.42-2.59 2.19 1.46-3.27 
Smoker 1.71 1.39-2.10 1.49 1.13-1.97 
Diabetic 1.47 1.04-2.08 1.80 1.18-2.74 
LDL-C 
<130 I I 
130-159 1.19 0.91-1.54 1.24 0.84-1.81 
>160 1.74 1.36-2.24 1.68 1.17-2.40 
HDL-C 
<35 1.46 1.15-1.85 2.08 1.33-.325 
35-59 I I 
>60 0.61 0.41-0.91 0.64 0.47-0.87 
Adapted from Wilson et al. Prediction of coronary heart disease using risk factor categories. Circulation. 
1998;97(18): 1837-1847. 
Table 5: Total CHD Risk bv A!!e in Patients Without Other Risk Factn~·* 
---I Age 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 
Gender 
Male 2% 3% 3% 4% 5% 7% 8% 10% 13% 
Female <2% <2% 2% 3% 5% 7% 8% 8% 8% 
' 
*10-year risk of total CHD for a non-smoking person without diabetes and with blood pressure <120/80 mmHg, total 
cholesterol <200 mg/dl, HDL cholesterol 2: 55mg/dl. Adapted from Grundy et al. Assessment of cardiovascular risk by use of 
multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and 
the American College of Cardiology. Circulation. 1999;100(13):1481-1492. 
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Table 6: Clinical Imolicaf fV 
-------- ----------.._--- -------- --.---.,--- L Is of 10 
--· --- ---- "---- CHDRisk 
10-YearCHD Clinical Implication Preventive Strategy Interventions 
Risk* 
<6-10% Encourage a healthy lifestyle. - Therapeutic lifestyle changes 
- Consider aspirin if risk is 2:6%. 
Low short-term No definitive treatment necessary. Raise awareness that risk factors imply - Treat hypertension to keep blood pressure 
risk. higher long-term risk of CHD <140/90. 
- Treat lipids per NCEP-ATP III guidelines 
- Smoking cessation. 
10-20% Patient -centered approach. - Therapeutic lifestyle changes 
- Daily aspirin. 
Intermediate These patients may need further risk Since is not clear whether more - Treat hypertension to keep blood pressure 
short-term risk. stratification to guide therapy. aggressive treatment is beneficial, <140/90. 
decisions about treatment need to reflect - Treat lipids per NCEP-ATP III guidelines 
the patient's values. - Smoking cessation. 
Take into account other risk factors that 
are not included in the Framingham 
equation, but that may influence the 
patient's overall risk. 
2:20% - Therapeutic lifestyle changes 
Prompt and aggressive risk factor - Daily aspirin. 
High short-term This level of risk is the same as reduction - Treat lipids with goal of 
risk someone who already has known LDL-C < IOOmg!dl. 
(CHD equivalent) CHD. - Tight control of blood pressure. If diabetic, 
target is <130/80. 
- Smoking cessation. 
···-- - ----------
See text for d1scusswn. 
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Table 7: Proposed Novel Risk Markers and Screening Tests for CVD 
Inflammatory Markers 
C-reactive protein 
Interleukin-6 (IL-6) 
Serum amyloid A 
Soluble CD-40 ligand 
Leukocyte count 
Vascular and cellular adbesion molecules 
Platelet-Related Factors 
Platelet aggregation 
Platelet activity 
Platelet size and volume 
Lipid-Related Factors 
Small dense LDL 
Lipoprotein (a) 
Remnant lipoproteins 
Apolipoproteins Al and B 
HDL subtypes 
Oxidized LDL 
Other Factors 
Homocyteine 
Brain natriuretic peptide (BNP) 
Lipoprotein-associated phospholipase A(2) 
Microalbuminuria 
P AI -1 genotype 
Angiotensin-converting enzyme genotype 
ApoE genotype 
Infectious agents: Cytomegalovirus, Chamydia 
pneumonia, Helicobacter pylori, Herpes simplex virus 
Psychosocial factors 
Screening Tests 
Ankle-brachial index (ABI) 
Carotid B-mode ultrasound to measure intima-media 
thickness 
Coronary calcium scoring with electron-beam computed 
tomography (EBCT) 
Brachial artery reactivity testing 
Cardiovascular magnetic resonance imaging (CMR) 
Arterial elasticity testing 
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Study/ Design & Calculated Intervention Endpoints Outcome 
Research Objective Setting Patient 
Level of 
CHD Risk1 
Hall et al." RCT 13%Low Patients alternately allocated to the (I) Change in Overall there were no differences 
2003 35%Mod experimental or control group. treatment ofDM; in the main outcomes. However, 
N~323 patients. 6 physicians Diabetes 52% High Experimental group patients had (2) Prescription of among the high risk patients 
Clinic, UK their risk score clearly documented lipid-lowering or (>20% 5 year risk) those in the 
To determine if documentation of a global CHD on the front of the chart. Control antihypertensive experimental group were more 
risk score improves management of risk factors patients did not. drugs, likely to be prescribed CV drugs 
among diabetic patients (3) Referral to a (p<0.02) 
dietician 
Ramachandran et al0 ". Cohort Mean 10· Postal Questiormaires containing 20 Proportion of There was no difference in the 
2000 study year risk: patient case scenarios. GPs were correct responses appropriateness of decision-
N ~ 61 physicians 28.9% asked to indicate whether lipid- based on UK making between GPs who used 
General lowering medication was indicated, guidelines (i.e. clinical perception as the sole 
To assess the appropriateness of lipid treatment Practices, and they were asked what method therapy indicated means of risk assessment and 
decisions made by GPs UK they used in assessing the patients for those with a 10- those who calculated CHD risk 
CHDrisk. year CHD risk (p~0.21). 
"'30%). 
Lowensteyn et al'"' RCT 63%"high"' Physicians were randomized to (I) The likelihood (I) The likelihood of high-risk 
1998 risk either the profile or control group. of returning for patients returning for follow-up 
Ndl58 patients, 253 physicians General Profile group received computerized follow-up at 3 was significantly greater in the 
practices, risk report. months, profile group. (2) Profile group 
To determine the feasibility of patient-specific Canada (2) Change in risk patients had significantly greater 
computerized CHD risk profiles as clinical factors over 3 reductions in lipid values and 
decision aids months calculated 8-yr CHD risk. No 
difference for other risk factors. 
---
Continued on next page 
Table lU tLontmueU): Lbaractensncs :stuUies AUUressmg Llinlcal Henents ot lilobal Klsk.1Scores 
Study/ Design & Calculated Intervention Endpoints Outcome 
Research Objective Setting Patient 
Level of 
CHDRisk1 
Montgomery et al.'' RCT Mean 5- Practices were randomized to one of (1) %of patients (1) No difference between groups 
2000 year CHD 3 arms: (I) computer-based clinical in each group with as to the proportion of patients 
N~ 614 patients, 27 practices General risk: 18.5% decision support system & CHD a 5-yr CHD risk still at high-risk at I year. (2) risk 
(74 physicians, 11 nurses) practices, risk chart, (2) CHD risk chart alone, 2:10o/o, (2) Blood calculation was associated with 
UK (3) usual care pressure, (3) lower mean systolic blood 
To investigate the effects of a computer-based Prescribing of pressure at 12 months and with an 
decision support system + risk chart on CVD drugs. increased likelihood of 
absolute CVD risk, blood pressure, and prescription of CV drugs 
prescribing ofCVD drugs (p<O.OI). 
N reflects number of participants enrolled, which is not necessarily the same as the number who completed follow-up. RCT ~ Randomized Controlled Trial. 
CV ~ Cardiovascular. ! As defined by the study authors. 
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Study/ Design & Calculated Intervention Endpoints Outcome 
Research Objective Setting Patient 
Level of 
CHDRiskl 
Connelly et a!.'" Cohort 81.5% Health screening including Scores on the health Men who were labeled as either 
1998 Low/Mod CHD risk calculation questionnaire at 3 high or low risk showed a 
N = 5772 patients General risk; 18.5% months follow-up. decrease in their psychological 
practices; High risk symptoms after labeling. 
To identify the psychological impact of labeling UK However, men who were labeled 
men as having above average risk for CHD 11moderate" risk actually had an 
increase psychological symptoms 
to "case" levels 
Marteau et al. RCT Not given Participants randomized to a Perceptions of health, No difference between groups. 
1996 CHD screening group or a the risk of suffering a 
N = 2984 married couples General control group. heart artack. and the 
practices; ability to reduce that 
To determine the whether a population-based UK risk at 1 year. 
intervention program to reduce CVD raises 
concerns about health or undermines a belief in 
the ability to reduce risk 
N reflects number of participants enrolled, which is not necessarily the same as the number who completed follow-up. RCT =Randomized Controlled Trial. 'As 
defmed by the study authors. 
_,,y, ___ ' 
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Lowensteyn et 
al72 
1998 
Montgomery et 
171 a. 
2000 
Fair 
For Studies Included in the Review 
blinding 
No information on baseline patient 
characteristics - no way to assess adequacy 
of randomization or for confounding 
Lack of treatment details 
1nly 6 hysicians included 
~adequate blinding 
Limited baseline patient data 
Physician groups not similar at baseline 
Only physicians were randomized; not 
patients 
Patients selected by physicians- potential 
for selection bias 
Lack of details on patients screened but not 
enrolled 
Substantial number of physicians did not 
enroll patients in study 
High patient drop-out rate 
Lack of treatment details 
- Not blinded 
Lack of treatment details 
The manner that risk charts were used was 
not clearly described 
Continued on next page 
Issues with External 
Validity 
Fair - Specialty 
population. 
- No information on 
baseline patient 
characteristics. 
Fair - Mechanism of 
risk score not reflective 
of actual practice 
- Limited baseline patient 
data 
Fair - Not entirely a primary 
prevention trial 
- Lack of treatment details 
- The manner that risk 
charts were used was not 
., 
Table 12 
Study 
1998 
Marteau et al. 
1996 
Study 
Design 
Rating 
I 
controlled 
Internal 
Validity 
Rating 
Poor 
of On" litv For Studies Included in the Review 
Not blinded 
Very little baseline patient information 
provided 
Lack of details about nature of risk score 
Lack of treatment details 
Very limited description of study 
procedures 
Not clear if blinded 
No baseline patient information provided 
External 
Validity 
Rating 
Issues with External 
Validity 
patient information 
provided 
Clinical relevance of 
psychological endpoints 
is unclear 
Lack of treatment details 
No baseline _ 
information provided 
Clinical relevance of 
psychological endpoints 
unclear 
series with or without intervention, or dramatic results from an uncontrolled experiment], III [expert opinion, case reports, descriptive 
studies]. See text for description of criteria for ratings of good, fair, and poor. 
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Table 13: Cases Included on Risk Score Study Questionnaire 
-
-
Case # ofNCEP Major 10-year CHD Aspirin Lipid- Anti- Rationale for Inclusion in 
Risk Factors Risk recommended Lowering hypertensive Study 
recommended recommended 
l. 58 year old woman 3 15% Yes Yes Yes Recognize OM as a CHD 
Type II diabetes equivalent; recognized 
Non-smoker lower blood pressure goal 
BP: 134/88 for diabetics. 
HbAlc: 7% 
Waist: 38" 
T. Chol: 201 mg!dl 
LDL-C: 129 mg!dl 
HDL-C: 42 mg!dl 
TG: 152 mg/dl 
2. 49 year old man 3 22% Yes Yes No Recognize someone with 
Smoker multiple risk factors and 
BP: 134/88 high risk. Recognize the 
FBG: l 05 mg!dl metabolic syndrome 
Waist: 41" 
T. Chol: 242 mg!dl 
LDL-C: 178 mg!dl 
HDL-C: 34 mg/dl 
TG: 155 mg/dl 
3. 62 year old woman 2 6% Yes Yes No Recognize someone with 
Non-smoker multiple risk factors but 
BP: 135/82 with low risk. Recognize 
On BP medication the metabolic syndrome. 
FBG: 98 mg!dl 
Waist: 34" 
T. Chol: 245 mg!dl 
LDL-C: 166 mg!dl 
HDL-C: 48 mg!dl 
TG: 155 mg/dl 
Continued on next page 
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Table 13 (C d): c Included RiskS Studv Quesf 
' 
--------J• ------ --
----
-
--------
Case # ofNCEP Major 10-year CHD Aspirin Lipid- Anti- Rationale for Inclusion in 
Risk Factors Risk recommended Lowering hypertensive Study 
recommended recommended 
4. 72 year old man 2 24% Yes Yes Yes Recognize the risk conferred 
Non-smoker by older age; especially in 
BP: 142/82 men. 
On BP medication 
FBG: 108 mg/d1 
Waist: 33" 
T. Chol: 200 mg/dl 
LDL-C: 130 mg/d1 
HDL-C: 42 mg/dl 
TG: 140 mg/dl 
5. 51 year old man I 5% No No No Recognize that not all 
Non-smoker middle-age men are higb 
BP: 126/78 risk. 
FBG: 99 mg/d1 
Waist: 33" 
T. Chol: 228 mg/dl 
LDL-C: 150 mg/dl 
HDL-C: 55 mg/dl 
T(i: 115 mg/dl 
-~·-- -----
Continued on next page 
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Table 13 (Continued): Cases Included on Risl,i_~C()re Study Questionnaire 
Case # ofNCEP Major 10-yearCHD Aspirin Lipid- Anti- Rationale for Inclusion in 
Risk Factors Risk recommended Lowering hypertensive Study 
reconunended reconunended 
6. 68 year old woman 3 10% Yes No No Recognize someone with 
Smoker multiple risk factors but 
BP: 138/78 only intermediate risk. 
On BP medication 
FBG: 99 mgldl 
Waist: 32" 
T. Chol: 208 mgldl 
LDL-C: 128 mgldl 
HDL-C: 50 mgldl 
TG: !50 mgldl 
7. 38 year old woman I 4% No No No Recognize someone with a 
Smoker risk factor but with low 
BP: 136/85 short-term risk. Recognize 
FBG: I 08 mgldl the metabolic syndrome. 
Waist: 36" 
T. Chol: 230 mgldl 
LDL-C: !59 mgldl 
HDL-C: 42 mg/dl 
TG: 145 mg/dl 
8. 45 year old man 2 14% Yes Yes No Recognize someone with 
Smoker multiple risk factors and 
BP: 136/84 intermediate risk. 
FBG: I 00 mg/dl 
Waist: 33" 
T. Chol: 228 mgldl 
LDL-C: 162 mgldl 
HDL-C: 43 mgldl 
TG: 115 mg/dl 
Continued on next page 
Table 13 (Continued): Cases Included on Risk Score Study Questionnaire 
Case # ofNCEP Major 10-yearCHD Aspirin Lipid- Anti- Rationale for Inclusion in 
Risk Factors Risk recommended Lowering hypertensive Study 
recommended recommended 
9. 41 year old woman 2 3% No Yes No Recognize someone with 
Smoker multiple risk factors but 
BP: 128/77 with low risk. 
FBG: I 05 mg/dl 
Waist: 34" 
T. Chol: 210 mg/dl 
LDL-C: !53 mg/dl 
HDL-C: 42 mg/dl 
TG: 125 mg/dl 
Mother had non-fatal 
MI at age 50 
10. 70 year old woman 2 4% No No No Recognize someone with 
Smoker but also has a multiple risk factors but 
BP: 115/80 negative risk factor with low risk. Recognize 
FBG: I 00 mg/dl that high HDL-C is a 
Waist: 31" negative risk factor 
T. Chol: 245 mg/dl 
LDL-C: 157 mg/dl 
HDL-C: 62 mg/dl 
TG: 128 mg/dl 
BP =Blood pressure; FBG =fasting blood glucose; Waist= waist circumference; T. chol =total cholesterol; TG = triglycerides. 
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Table 15: P f f Subiects Who Made a C tA: 
------------------ ------·- ---- ---------------------------------
fCHDRisk 
Case Overall Group I Group2 P value 
(Risk Score) (No Risk Score) 
I 41.2 42.1 49.8 0.861 
2 52.1 55.3 48.5 0.569 
3 47.1 59.5 33.3 0.029 
4 34.3 54.0 12.1 <0.001 
5 84.5 81.6 87.9 0.464 
6 77.1 79.0 75.0 0.695 
7 73.2 76.3 69.7 0.530 
8 70.4 73.7 66.7 0.518 
9 31.0 50.0 9.1 <0.001 
10 44.3 70.3 15.2 <0.001 
All values represent the proportion of subjects who correctly identified the patient's categorical level of I 0-year CHD 
risk (low- intermediate- high). 
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Table 16: Proportion of Subjects Who Correctly Correlated the Numeric Risk 
d the Risk Cat ~--- -- - - ~ ~ ~ e ory 
Case Overall Group l Group 2 P value 
(Risk Score) (No Risk Score) 
I 50.8 63.2 34.5 0.020 
2 57.1 62.2 51.5 0.369 
3 53.0 59.4 45.2 0.239 
4 59.0 54.1 65.5 0.347 
5 87.0 86.8 87.1 0.975 
6 68.7 79.0 55.2 0.038 
7 73.1 76.3 69.0 0.501 
8 71.0 73.7 67.7 0.588 
9 52.1 50.0 54.6 0.702 
10 69.6 70.3 68.8 0.891 
All values represent the proportion of subjects who correctly correlated the patient's categorical level of 10-year CHD 
risk (low- intermediate- high) with the corresponding numeric risk range (<10%, 10-19%, 2:20%). For Group 2 this 
signifies that the categorical risk level selected by the subject was correctly matched with an appropriate numeric risk. 
For Group I, which was provided with a numeric risk score, this signifies that the subject correctly identified the 
categorical risk level that corresponded with the numeric estimate that was provided. 
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Table 18: Proportion of Subjects Who Made Correct Recommendations for All Three 
Preventive Interventions: Case-bv-C 
- --· ----·- ------.--------- ----- ·-
-----
Case# Overall Group 1 Group 2 P value 
(Risk Level) (Risk Score) (No Risk Score) 
N~71 N~38 N~33 
I (intermediate) 78.9 76.3 81.8 0.571 
2 (high) 50.7 44.7 57.6 0.280 
3 (low) 31.0 21.1 42.4 0.052 
4 (high) 28.2 26.3 30.3 0.710 
5 (low) 45.1 47.4 42.4 0.676 
6 (intermediate) 26.8 26.3 27.3 0.928 
7 (low) 39.4 39.5 39.4 0.995 
8 (intermediate) 32.4 42.1 21.2 0.061 
9 (low) 16.9 26.3 6.1 0.023 
10 (low) 19.7 23.7 15.2 0.367 
All values represent the proportion of subjects who made correct (guideline-directed) decisions about aspirin therapy, 
lipid· lowering therapy, and anti-hypertensive therapy. 
Table 19: Proportion of Subjects Who Made Correct Recommendations for Aspirin 
Theranv: Case-bv-C 
---
Case# Overall Group 1 Group2 P value 
(Risk Level) (Risk Score) (No Risk Score) 
N=7l N=38 N=33 
I (intermediate) 97.2 97.4 97.0 0.919 
2 (high) 87.3 84.2 90.9 0.397 
3 (low) 69.0 66.0 72.7 0.528 
4 (high) 81.7 84.2 78.8 0.556 
5 (low) 59.2 57.9 60.6 0.817 
6 (intermediate) 77.5 79.0 75.8 0.748 
7 (low) 71.8 73.7 69.7 0.710 
8 (intermediate) 70.4 81.6 57.6 0.027 
9 (low) 36.6 55.3 15.2 <0.001 
10 (low) 29.6 36.8 21.1 0.150 
All values represent the proportion of subjects who made correct (guideline-directed) decisions about aspirin therapy . 
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Table 20: Proportion of Subjects Who Made Correct Recommendations for Lipid-Lowering 
Theraov: Case-bv-C 
---
Case# Overall Group 1 Group 2 P value 
(Risk Level) (Risk Score) (No Risk Score) 
N=71 N=38 N=33 
I (intermediate) 94.4 92.1 97.0 0.375 
2 (high) 92.6 94.7 90.9 0.530 
3 (low) 64.8 57.9 72.7 0.192 
4 (high) 35.2 36.8 33.3 0.758 
5 (low) 71.8 71.1 72.7 0.876 
6 (intermediate) 77.5 76.3 78.8 0.804 
7 (low) 53.5 57.9 48.5 0.428 
8 (intermediate) 80.3 89.5 69.7 0.037 
9 (low) 64.8 57.9 72.7 0.192 
10 (low) 49.3 52.6 45.5 0.546 
All values represent the proportion of subjects who made correct (guideline-directed) decisions about lipid-lowering therapy. 
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Table 21: Proportion of Subjects Who Made Correct Recommendations for 
Antihvoertensive Theraov: Case-bv-C - _.._._ 
Case# Overall Group l Group 2 P value 
(Risk Level) (Risk Score) (No Risk Score) 
N=7l N=38 N=33 
I (intermediate) 88.7 86.8 90.9 0.589 
2 (high) 61.9 60.5 63.6 0.788 
3 (low) 74.8 71.1 78.8 0.455 
4 (high) 93.0 97.4 87.9 0.119 
5 (low) 100 100 100 
-
6 (intermediate) 43.7 42.1 45.5 0.777 
7 (low) 69.0 71.1 69.0 0.690 
8 (intermediate) 60.6 60.5 60.6 0.995 
9 (low) 97.2 100 93.9 0.124 
10 (low) 97.2 97.4 97.0 0.919 
All values represent the proportion of subjects who made correct (guideline-directed) decisions about antihypertensive therapy. 
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A ~ppen d" 1 R IX : ecommen d ed Interventions or the Prevention o f Cardiovascular Disease: 
Level of Preventive USPSTF/TFCPS Guidelines Other Major Guidelines 
Prevention Intervention 
Primordial Physical - Point-of-decision prompts 
Prevention Activity79 - Community wide educational campaigns about the benefits 
of physical activity. 
-
School-based physical education 
- Social support interventions if! community settings 
- Individually-adapted health behavior change programs 
- Creation of or enhanced access to places for physical 
activity combined with informational outreach activities 
Nutrition - TFCPS Reviews are currently in progress~u 
- USPSTF recommends intensive behavioral dietary 
counseling for adults with risk factors for CVD. {B)81 
Tobacco - Increase the price of tobacco products 
Prevention 52 - Mass media campaigns 
- Smoking bans and restrictions 
Primary Screening for - Screen all adults aged 18 and older for HTN (A) JNCVII": 
Prevention Hypertension - Screen all adults for H1N 
AHA': 
-
Screen q2 years beginning at age 20. 
Screening for - Routinely screen men 2:35 years old and women 2::45 years NCEP-ATP m•: 
Lipid old. Treat abnormal lipids in those who are at increased - Screen q5 years beginning at age 20. 
Disorders risk for CHD. (A) AHAs3: 
-
Screen younger adults (men 20-35 years old and women 20- - Screen q5 years beginning at age 20; q2 
45 years old) ifthey have other CHD risk factors. (B) years if risk factors are present 
f 
l 
I 
ADA84: 
- Screen adult diabetics annually. Screen 
biannually if lipid profiles is low risk. 
Type II - Screen all adults with HTN or hyperlipidemia for type II AHA": 
Diabetes85• 86 DM. (B) - Screen ALL adults with a FBG q5 years 
- The TFCPS strongly recommends a multi-component starting at age 20; q2 years if risk factors 
approach to healthcare delivery, including community- are present 
based diabetes self-management education as well as ADAs7: 
individual case management, for all persons with diabetes 
- Consider screening q3-year in those ~45 
years old; particularly ifBMI 2:25 kg/m2. 
Consider screening at a younger if 
overweight or other CVD risk factors are 
present. 
Aspirin - Discuss the potential benefits and harms of aspirin AHA": 
chemoprevention with adults who are have a >6% 1 0-year 
- Use ASA for those with a .2:10% 10-year 
risk for CHD (A) CHD risk 
ADA88: 
-
Use ASA for patients with type 2 
diabetes who are >40 years old or who 
have CVD risk factors 
Screening for - Screen all adults for obesity (B) AHA": 
Obesity89 - Offer INTENSIVE counseling and behavioral interventions - Record BMI and waist eire. at least q2 
to promote sustained weight loss for OBESE adults. (B) years. 
- Initiate a weight-management program 
for overweight and obese patients 
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Smoking - Screen all adults and provide tobacco cessation AHA": 
Cessation 77• 82 interventions for those who use tobacco products. (A) - Screen for tobacco use at every visit and 
- Screen all pregnant women and provide augmented advise all smokers to quit. Assist by 
pregnancy-tailored counseling to those who smoke. (A) counseling and arrange for follow-up, 
- The TFCPS strongly recommends multi-component referral, and pharmacotherapy when 
interventions that include patient support, provider reminder appropriate. 
systems and an educational component. 
-
Reducing patient out-of-pockets costs for effective 
cessation therapies is recommended by the TFCPS 
Secondary Interventions are similar to primary prevention, but treatment is more aggressive because of higher baseline risk for 
& Tertiary CVD events. 
Prevention 
" 
, 
" 
, Only USPSTF recommendatiOns with ratmgs of A or B are listed. 
USPSTF =U.S. Preventive Services Task Force; TFCPS =Task Force on Community Preventive Services; AHA= American Heart 
Association; ADA= American Diabetes Association; NCEP-ATP III= National Cholesterol Education Program Adult Treatment Panel 
III; JNC 7 =The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure; HTN =hypertension; FBG =fasting blood glucose; ASA =aspirin; BMI =body mass index; 
Recommendation 
A The USPSTF strongly recommends that clinicians routinely provide [the service] to eligible patients. 
(The USPSTF found good evidence that [the service] improves important health outcomes and 
concludes that benefits substantially outweigh harmS.) 
B The USPSTF recommends that clinicians routinely provide [the service] to eligible patients. (The 
USPSTF found at least fair evidence that [the service] improves important health outcomes and 
concludes that benefits outweigh harms.) 
c The USPSTF makes no recommendation for or against routine provision of[the service]. (The 
USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes 
that the balance of benefits and harms is too close to justifY a general recommendation.) 
D The USPSTF recommends against routinely providing [the service] to asymptomatic patients. (The 
USPSTF found at least fair evidence that rthe service] is ineffective or that harms outweigh benefits.) 
I The USPSTF concludes that the evidence is insufficient to recommend for or against routinely 
providing [the service]. (Evidence that [the service] is effective is lacking, of poor quality, or 
conflicting and that the balance of benefits and harms cannot be determined.)' 
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Appendix 2: Scoring for Global Risk Assessment (Adjusted Framingham Scoring) 
Risk Points 
Risk Factor Men Women Adding Up 11e Points 
.. y Age_ Cholesterol_ 
<34 -1 -9 Dlabe!eL. HDL ChOlesteroL 
35-39 0 -4 Smoker_ Blood Pres&Jrl!_ 
4o-44 1 0 
45-49 2 3 Tollll_ 
5()-54 a 6 
51)-59 4 7 Absolute Risk (Hard CHD), % 
60-64 5 s RlskPolnls Men Women 
65-$ 6 9 
7(}-74 7 10 1 2 1 
2 ~ 2 Total cl1orestero~ mgtdL ~ 
<100 -a -2 a 4 2 
169-199 0 0 4 5 2 
20(}-239 1 1 5 6 2 
24(}-279 2 2 6 7 2 
""280 3 3 7 9 3 
HDL cholesterol, mgtdL 8 13 3 
<35 2 5 9 16 3 
35-44 1 2 10 20 4 
45-49 0 1 11 25 7 
5o-59 -1 0 12 30 8 
l!:60 -2 -3 13 35 11 
Blood pressure, mm Hg 14 45 13 
<120 0 -3 15 15 
121}-129 0 0 16 18 
13(}-139 1 1 17 20 
141}-159 2 2 
>160 3 • .,
PIMma glucose. mgldL 
<110 0 0 
111}-126 1 2 
>126 2 4 
Smoker 
•ro 0 0 
Yes 2 2 
Adapted from Grundy38 
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Appendix 3: Example of Case Presentation on the Risk Score Questionnaire Presented to 
Group 1. 
Case 1: A 58 year old woman with type II diabetes. She is a life-long non-smoker. She is 
asymptomatic, and she has no history of CHD. Her calculated 10-year risk of CHD is 15%. 
Blood pressure: 134/88 
Hemoglobin Ale: 7.0% 
Waist circumference: 38 inches 
Lipid panel: T. Chol: 201 mgldl 
LDL-C: 129 mg/dl 
HDL-C: 42 mg/dl 
TG: 152 mg/dl 
1.1: How would you categorize this patient's risk of developing CHD over the next 1 0 years? 
1. Low 2. Intermediate 3. High 
1.2: Does this patient have the metabolic syndrome? 
No Yes 
Which of the following would you recommend? (Circle all that apply) 
1.3: Therapeutic lifestyle changes? No Yes 
(Intensive patient oriented counseling on physical 
activity, diet, and, where indicated, smoking 
cessation) 
1.4: Daily aspirin? No Yes 
1.5: Lipid lowering medication? No Yes 
1.6: Blood pressure lowering medication? No Yes 
1.7: High sensitivity C-reactive protein No Yes 
(hs-CRP) testing? 
1.8: Coronary calcium scoring with electron-beam No Yes 
computed tomography (EBCT)? 
1.9: Exercise Treadmill Testing (ETT)? No Yes 
1.10: Ankle-brachial index (ABI) measurement? No Yes 
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